A Critical Review of Adverse Effects to the Kidney: Mechanisms, Data Sources and In Silico Tools to Assist Prediction by Pletz, J et al.
 Pletz, J, Enoch, SJ, Jais, DM, Mellor, CL, Pawar, G, Madden, JC, Webb, SD, 
Tagliati, C and Cronin, MTD
 A Critical Review of Adverse Effects to the Kidney: Mechanisms, Data 
Sources and In Silico Tools to Assist Prediction
http://researchonline.ljmu.ac.uk/id/eprint/9535/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Pletz, J, Enoch, SJ, Jais, DM, Mellor, CL, Pawar, G, Madden, JC, Webb, SD, 
Tagliati, C and Cronin, MTD (2018) A Critical Review of Adverse Effects to 
the Kidney: Mechanisms, Data Sources and In Silico Tools to Assist 
Prediction. Expert Opinion on Drug Metabolism and Toxicology. ISSN 1744-
LJMU Research Online
1 
 
A CRITICAL REVIEW OF ADVERSE EFFECTS TO THE KIDNEY: MECHANISMS, DATA SOURCES 
AND IN SILICO TOOLS TO ASSIST PREDICTION 
 
 
J. Pletz1, S.J. Enoch1, D.M. Jais1, C.L. Mellor1, G. Pawar1, J.C. Madden1, S. D. Webb2, C. 
Tagliati3, M.T.D. Cronin*1 
1School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom 
Street, Liverpool L3 3AF, England 2Department of Applied Mathematics, Liverpool John 
Moores University, Liverpool, England 3Departamento de Análises Clínicas e Toxicológicas, 
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil 
 
*Corresponding author: Tel. +44 151 231 2402; e-mail address: M.T.Cronin@ljmu.ac.uk 
(Mark Cronin) 
 
  
2 
 
ABSTRACT 
Introduction: The kidney is a major target for toxicity elicited by pharmaceuticals and environmental 
pollutants. Standard testing which often does not investigate underlying mechanisms has proven not 
to be an adequate hazard assessment approach. As such, there is an opportunity for the application 
of computational approaches that utilise multi-scale data based on the Adverse Outcome Pathway 
(AOP) paradigm, coupled with an understanding of the chemistry underpinning the molecular 
initiating event (MIE) to provide a deep understanding of how structural fragments of molecules 
relate to specific mechanisms of nephrotoxicity.  
The aim of this investigation was to review the current scientific landscape related to computational 
methods, including mechanistic data, AOPs, publicly available knowledge bases and current in silico 
models, for the assessment of pharmaceuticals and other chemicals with regard to their potential to 
elicit nephrotoxicity. A list of over 250 nephrotoxicants enriched with, where possible, mechanistic 
and AOP-derived understanding was compiled.  
Expert opinion: Whilst little mechanistic evidence has been translated into AOPs, this review 
identified a number of data sources of in vitro, in vivo and human data that may assist in the 
development of in silico models which in turn may shed light on the inter-relationships between 
nephrotoxicity mechanisms. 
Key words: kidney, nephrotoxicity, in silico, computational models, (Q)SAR, mechanisms 
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1.0 INTRODUCTION 
Acute renal failure in critically ill patients, as well as those with chronic kidney disease, was related 
to drug therapy in about 20% and 35% of cases reported respectively [1–3]. As a result of such 
toxicity, six prescription drugs (beta-ethoxy-lacetanilanide, bucetin, phenacetin, suprofen, 
thiobutabarbitone and zomepirac) were withdrawn from the market between 1983 and 1993, at 
great cost, due to renal adverse events, solely or in combination with other adverse effects [4]. 
Therefore, eliminating drug candidates which cause these adverse effects at early stages of drug 
design is extremely important to ensure patient safety. However, despite its importance for drug 
development and for many other industrial sectors, nephrotoxicity is a complex endpoint and often 
occurs gradually or as a complication related to other pathologies such as diabetes [5] and 
hypertension [6], thus making it difficult to identify even with sophisticated toxicity testing or clinical 
trials.  
 
Established approaches to identify kidney toxicants have traditionally relied on extensive animal 
testing. However, the “Toxicity Testing in the 21st Century” paradigm calls for use of alternative 
testing strategies [7]. Computational approaches such as (quantitative) structure-activity 
relationships ((Q)SARs)1 and structural alerts (SAs) are currently used to predict a variety of organ 
toxicities e.g. for hepatic toxicity [8]. In recent years, much emphasis has been placed on 
understanding the underlying mechanisms of liver toxicity which have led to the development of 
several Adverse Outcome Pathways (AOPs), many SAs and QSARs [8–10]. The relative successes with 
the development of alternatives for identifying liver toxicants has demonstrated that success can be 
achieved and it is possible to address other organ level toxicity in a similar manner. Thus, there is a 
growing movement to other important organs in the body in order to reach the ultimate goal of 
mapping the toxicological pathways of pharmaceuticals, cosmetics and other chemicals within 
humans [11].  
 
The kidney is a major target for toxicity elicited by pharmaceuticals and environmental pollutants. 
Approximately 20% of acquired acute kidney injury (AKI) cases are associated with the use of drugs 
[12]. Being burdened with multiple comorbidities, the average patient tends to take several 
medications which may cause kidney injury [13]. Environmental chemicals including certain heavy 
metals, trichloroethylene, and bromobenzene have been known to cause nephrotoxic effects [14]. 
One of the reasons for the kidney being a key target of toxicity may be related to the kinetics of 
                                                          
1In this paper, (Q)SAR will be mentioned if both SAR and QSAR are referred to while SAR and QSAR are stated 
to refer to either approach specifically. 
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many xenobiotic substances. High exposures are reached because of a high blood flow in the kidneys 
and extensive reabsorption, predominantly in the proximal tubule.  
 
Considering that renal toxicity is a major drug safety issue, standard testing which often does not 
investigate underlying mechanisms has proven not to be an adequate assessment approach. As 
such, this is an opportunity for the application of computational approaches that utilise the AOP 
paradigm coupled with an understanding of the chemistry underpinning the MIE [10,15] to provide a 
deep understanding of how structural fragments of molecules relate to specific mechanisms of 
nephrotoxicity. In addition in silico approaches using multi-scale data have been demonstrated to 
provide valuable insight into hepatotoxicity pathways and the assessment of inter-individual 
variability [16,17]. Multi-scale models incorporate data which span various biological scales, i.e. 
population, individual whole body, tissue and multi-cellular, and sub-cellular metabolic and signalling 
pathways [18]. As multi-scale modelling answered some of the pressing questions regarding adverse 
events in the liver, it is likely to hold the same potential for kidney and bladder related toxicity.  
 
The aim of this investigation was to review the current scientific landscape related to computational 
methods for the assessment of pharmaceuticals and other chemicals with regard to their potential 
to elicit nephrotoxicity and to provide a future perspective for this field of research. Here, the term 
‘’nephrotoxicity’’ includes both kidney toxicity and bladder disorders. To achieve the aim, the 
current data relating to this endpoint, which are accessible in publicly available knowledge bases and 
could aid the development of computational methods for this toxicity endpoint, were also reviewed. 
In addition, current in silico models (SAs, QSARS, mechanistic models) related to nephrotoxicity were 
examined and existing knowledge of relevant toxic mechanisms assessed in order to understand to 
which extent these have already been covered by existing approaches, including AOPs. Clinical 
manifestations of renal disease including oedema, uraemia, hyperphosphatemia, hyperkalaemia, 
hypocalcaemia, acidosis, hyperparathyroidism, and anaemia [19] go beyond the scope of this study 
and, therefore, were not considered. As uses of in silico toxicology approaches are ever increasing, 
this investigation also attempted to assess to what extent future models may inform hazard 
assessments and drug design, and what is needed to drive this field forward.  
 
2.0 MECHANISMS OF KIDNEY AND BLADDER TOXICITY 
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In order to understand the highly specific adverse effects that may take place in the kidney and 
associated organs, it is essential to appreciate its function and physiology. The key function of the 
kidney is to eliminate endogenous waste products, control and maintain volume levels, endocrine 
function, electrolyte content and acid-base balance [20,21]. As major site of elimination of drugs and 
other chemical compounds, the kidney is a common target for toxicity. Since the kidney is highly 
vascularised, receiving about 25% of the resting cardiac output, it is exposed to exogenous 
compounds in large quantities through systemic circulation [20,22]. The functional units of the 
kidney are nephrons - each kidney contains around one million nephrons, which consist of the 
glomerulus – a ball of capillaries –, Bowman’s capsule, and the tubular element (proximal tubule, 
Loop of Henle, distal tubule and collecting duct). When a substance reaches the glomerulus through 
the afferent arteriole it is likely to be filtered into the proximal tubules where the vast majority is 
reabsorbed back into the blood [23]. Compound accumulation and “local” toxic metabolite 
formation may occur, making the kidney vulnerable to toxicity via various and simultaneously 
occurring mechanisms [12,20,22]. 
 
As a result of the physiology, there are four main mechanisms of drug-induced renal toxicity which 
are most commonly manifested as acute kidney injury, namely haemodynamic alteration, (proximal 
and distal) tubular cell toxicity, (tubular, interstitial, tubulo-interstitial and glomerular) nephritis and 
tubular obstruction [24,25]. Comparatively little is known about bladder toxicity as a whole and less 
about its underlying mechanisms. However, an understanding of mechanisms, such as it is, will assist 
in the development of in silico models as well as the organisation of the associated data. Figure 1 
shows the sites of the main mechanisms of chemical-induced kidney toxicity. 
 
A consideration of mechanistic toxicology also provides the opportunity to link to relevant Adverse 
Outcome Pathways (AOPs). The AOP framework facilitates the organisation of mechanistic 
knowledge and grants validity and robustness to data included in the OECD-sponsored AOP 
Knowledge Base (AOP-KB), [26, http://aopkb.org]. Mechanistic data gathered and organised in the 
form of AOPs serve as a robust basis for the development of computational toxicology models 
[10,27]. If an MIE and/or Key Events (KEs) have been defined and respective data are available, a 
prediction approach to estimate a substance’s potential to elicit one of more of these may be 
achieved using the knowledge in the AOP-KB and the public literature. Table 1 provides a starting 
point for in silico analyses based around the MIE in particular. The individual endpoints and apical 
effects are described in more detail in the remainder of Section 2. Additionally, AOPs may aid the 
grouping of chemicals for read-across [10]. Only a handful of kidney and bladder related AOPs have 
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been developed and proposed so far which implies that only a small amount of MIEs and KEs have 
been defined. Table 1 provides an overview of relevant AOPs that exist at the time of manuscript 
preparation, as sourced from the AOP Wiki [28, https://aopwiki.org], which is one key resource.  
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Figure 1: Sites and mechanisms of chemical-induced renal toxicity and respective substances 
potentially causing an effect at each [adapted from 25].  
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Table 1: Mechanisms of kidney toxicity, related (groups of) substances, and established and proposed MIEs and AOPs directly or indirectly associated with 
kidney toxicity   
Mechanism Overview MIE AOP Compounds Biomarkers 
Haemodynamic 
alteration 
 
 
Impaired 
autoregulatory 
capacity of the renal 
vasculature to 
vasodilate or 
vasoconstrict 
leading to a reduced 
GFR 
 
 
 
 
 
 
 
 
COX-1 and/or COX-2 inhibition leading to reduced 
prostaglandin synthesis and uncontrolled renal 
vasoconstriction (aspirin, other NSAIDs, calcineurin 
inhibitors) [29,30] 
AOP proposed by Lhasa Ltd. [29] 
ACE inhibitors, ARBs, 
NSAIDs (e.g. aspirin), 
amphotericin B, tacrolimus, 
radiocontrast agents, 
calcineurin inhibitors 
(cyclosporine, tacrolimus) 
[12,25] 
IL-18I), lipocalin 2 
(LCN-2 aka NGAL)II) 
[31] 
Prevention of formation of angiotensin II (ACE 
inhibitors) [32] 
No AOP found 
Blockage of angiotensin II type 1 (AT1) receptors 
(ARBs) [33] 
No AOP found 
Increase endothelin and thromboxane and activation 
of the renin-angiotensin system (RAS) 
(vasoconstriction), and reduction prostacyclin, 
prostaglandin E2 and nitric oxide (NO) (vasodilation) 
(calcineurin inhibitors) [30] 
No AOP found 
Changing vascular smooth muscle cell permeability, 
cell depolarization with resultant opening of voltage-
dependent calcium channels and muscle cell 
contraction (potential mechanism for amphotericin B) 
[34,35] 
No AOP found 
 
 
 
 
 
 
 
 
 
 
Metabolisation by oxidase in hepatocyte to 
benzoquinoneimine, followed by formation of GSH S-
conjugates (4-aminophenol) [36] 
OECD ENV/JM/MONO(2011)8: 
Nephrotoxicity induced by 4-
aminophenols [36] 
 
 
 
 
 
 
 
 
 
 
 
clusterinIII) , β2-
Mitochondrial toxicity pathways:  
a) Mitochondrial DNA incorporation (stavudine, 
AOP proposed by Lhasa Ltd. 
(stavudine, cidofovir) [37] 
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Proximal and 
distal tubular 
cell toxicity 
Extensive cellular 
uptake and intra-
cellular 
accumulation 
inducing 
compromised 
mitochondrial 
respiration, 
oxidative stress, and 
the activation of 
intrinsic apoptotic 
and necrotic 
pathways 
cidofovir) [37] 
b) Mitochondrial DNA polymerase gamma inhibition 
(stavudine, cidofovir) [37] 
c) Depletion of SH-groups leading to ROS induction 
(cisplatin) [44] 
 
aminoglycoside antibiotics, 
amphotericin B, 4-
aminophenols, cisplatin, 
nucleotide and nucleoside 
antivirals (stavudine, 
cidofovir) [25,36,37] 
microglobulinIV) , 
cystatin CV) , heme 
oxygenase-1VI) , IL-
18I) , lipocalin 2 
(LCN-2 aka NGAL)II) , 
KIM-1VII) , miR-34aIX) 
[31,38–43] 
Accumulation-induced lysosomal effects:  
a) accumulation induced lysosomal leakage leading to 
tubular dysfunction (aminoglycosides) [45] 
b) fusion of compound-containing pinocytic vacuoles 
and lysosomes causing osmotic nephrosis (contrast 
agents) [46] 
No AOP found 
After moving through cellular membrane, 
polyunsaturated region participates in auto-oxidation, 
lipid peroxidation and cell membrane damage; forming 
pores (amphotericin B) [34,35] 
No AOP found 
 
 
 
 
 
Tubular, 
interstitial, 
tubulo-
interstitial and 
glomerular 
nephritis  
 
 
 
 
Inflammatory 
changes in the 
glomerulus, 
interstitial and 
tubular cells 
predominantly 
caused by immune 
Interaction with hOAT1 and 3, accumulation within 
proximal tubule cells, followed by 
uncoupling/inhibition of mitochondrial oxidative 
phosphorylation and tubular/papillary necrosis 
(aspirin)* [29] 
AOP proposed by Lhasa Ltd. [29] 
NSAIDs (indomethacin, 
phenylbutazone, 
mefenamic acid, aspirin); 
antibiotics (cephalosporins, 
ciprofloxacin, ethambutol, 
isoniazid, macrolides, 
penicillins, rifampicin, 
tetracycline); loop 
(furosemide), potassium-
sparing (triamterene) and 
thiazide diuretics; proton 
 
 
 
 
 
 
 
 
 
IL-18I); lipocalin 2 
(LCN-2 aka NGAL)II); 
Production of inflammatory response triggering TNF-α 
(cisplatin) [44,53] 
No AOP found 
Formation of immune complex deposits (methicillin, 
rifampin, allopurinol, phenytoin) [47] 
No AOP found 
Formation of drug-protein hapten conjugates in renal 
tissue which elicit an immunogenic response 
No AOP found 
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mechanisms 
resulting in fibrosis 
and renal scarring  
(sulfamethoxazole metabolite = 
nitrososulfamethoxazole, methicillin) [47] 
pump inhibitors 
(omeprazole); allopurinol, 
lithium, aristolochic acid, 
phenytoin, propylthiouracil, 
ranitidine [12,25,29,47–49] 
osteopontinVIII) 
[42,50–52] 
(Event 244 (AOP 38):Protein alkylation)** [28] 
(AOP 38: Protein alkylation 
leading to liver fibrosis)** [28] 
Tubular 
obstruction 
Crystal precipitation 
within the renal 
tubule depending 
on urinary pH and 
favoured by high 
concentrations in 
the urine 
OAT interaction causing secretion via proximal tubule 
cells, accumulation and crystal formation in urine 
leading to concentration in renal tissue/tubule and 
obstructive nephropathy (acyclovir) [37] 
AOP proposed by Lhasa Ltd. [37] 
antibiotics (e.g. ampicillin, 
ciprofloxacin, vancomycin 
and sulphonamides), 
antivirals (e.g. indinavir and 
acyclovir), methotrexate 
[12,37,54] 
ClusterinIII), lipocalin 
2 (LCN-2 aka 
NGAL)II), IL-18I), 
KIM-1VII) [52,55] 
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* Interstitial nephritis is not the adverse outcome of these AOPs. However, as NSAIDs have been associated with this mechanism of nephrotoxicity, and KEs, e.g. ROS production and necrosis, 
are part of this pathway, these AOPs were allocated here. 
** This AOP is not directly related to nephrotoxicity but may be relevant for these pathways. 
I) IL-18: inflammatory response, activating NFκB in response to ischemia-reperfusion injury of renal tubules (e.g. after contrast agent exposure) 
II) LCN-2, NGAL: maximally expressed in kidney after early ischemic injury, in response to contrast agents; important mediator of innate immune responses 
III) Clusterin: associated with membrane recycling, cell repair, ischemic injury in proximal and distal tubule 
IV) β2-microglobulin: early marker of tubular injury 
V) Cystatin C: related to ischemic injury in proximal tubule 
VI) Heme oxygenase-1: changes in response to ischemic and cisplatin-induced injury 
VII) KIM-1: found in urine after proximal tubular cell injury 
VIII) Osteopontin: associated with accumulation of macrophages, expressed in the distal convoluted tubules, the thick ascending limbs of the loop of Henle  and the proximal tubule 
IX) miR-34: was upregulated following cisplatin induced acute kidney injury, may play a cytoprotective role for cell survival 
Abbreviations:  
ACE (angiotensin-converting enzyme) inhibitors; ARBs (angiotensin receptor blockers);  
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2.1 Haemodynamic alteration 
The kidney auto-regulates the pressure within the glomerulus by adjusting the afferent and efferent 
arterial tone to maintain the glomerular filtration rate (GFR) and urine output [12]. GFR is one of the 
key parameters to assess intraglomerular haemodynamics as it estimates the volume of blood 
filtered through the glomeruli per minute [19]. The GFR value considered normal in a healthy adult – 
standardised for a body surface area of 1.73m2 – is around 100-120 mL per minute [19,56].  
 
Patients with normal renal function who are being treated for hypertension generally do not 
encounter an increase in serum creatinine levels [33]. However, patients with chronic renal 
insufficiency and hypertension do when using antihypertensive drugs. A combination of factors 
related to chronic hypertension, such as structural and functional changes in small vessels of the 
kidney, contribute to a decrease in autoregulatory capacity of the renal vasculature leading to a 
reduced GFR and an increase in serum creatinine concentrations [33].  
 
An excessive lowering of blood pressure through the use of medication may cause a decrease in 
intraglomerular pressure which may be exacerbated by a decline of efferent arteriole resistance due 
to vasodilation and/or afferent vasoconstriction [33,57]. The use of angiotensin-converting-enzyme 
(ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with such effects, in 
particular with reducing efferent arteriolar tone. However, in patients with chronic kidney disease 
hypertension is common and a risk factor for the progression of renal damage [58]. Both, ACE 
inhibitors and ARBs are prescribed for their renoprotective effects in anti-hypertensive therapy, in 
combination to treat heart failure and CKD with proteinuria [59–62] even though this practice has 
been debated particularly for CKD patients aged 65 and older [63,64]. Also, careful dose titration is 
judged essential for ACE inhibitors [65] which indicates a narrow therapeutic index. ACE inhibitors 
prevent the formation of angiotensin II, a potent vasoconstrictor, which acts on vascular smooth 
muscle cells, with salt- and fluid-retentive properties [32].  
 
Intravascular volume depletion may induce adverse effects of ACE inhibitors on the kidney [33]. 
ARBs also target the angiotensin II pathway by blocking angiotensin II type 1 (AT1) receptors while 
not acting on angiotensin II type 2 (AT2) receptors which are stimulated to a higher extent as a result 
of higher circulating angiotensin II concentrations [33]. AT1 receptors are primarily on efferent 
vessels increasing vasoconstriction if activated while AT2 receptors are predominantly found on 
afferent vessels [33,66–68]. AT2 receptor binding has been associated with antagonised renal 
vasoconstrictor response and natriuresis [69,70]. 
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Even though ACE inhibitors and ARBs are considered renoprotective administered on their own and 
to counteract hypertension, they may aggravate nephrotoxic effects in combination with other drugs 
such as non-steroidal anti-inflammatory drugs (NSAIDs) and diuretics [71]. NSAIDs are known to 
cause alterations to intraglomerular haemodynamics by inhibiting either one or both isoenzymes of 
cyclooxygenase (COX-1 and COX-2) and, as a result, suppressing prostaglandin synthesis [24]. 
Prostaglandins mediate arteriolar vasodilation [72]. In certain conditions of decreased renal 
perfusion, e.g. cirrhosis and congestive heart failure, or volume depletion, renal function is 
increasingly dependent on prostaglandins [72,73]. In these instances, (selective and non-selective) 
NSAIDs used at high doses are associated with an increased risk of acute kidney failure [24]. An AOP 
was proposed describing this pathway [29]. 
 
A number of drugs induce renal dysfunction via more than one pathway. In the case of amphotericin 
B both haemodynamic and tubular adverse effects have been observed. The compound causes 
vasoconstriction of the renal arteriae, a subsequent decrease in renal blood flow and GFR, and 
polyuria [74]. On a cellular level, amphotericin B causes modifications in cell membrane integrity and 
increased influx of Ca2+ into the cytoplasm via newly formed pores [74–76]. These may lead to 
tubular cell toxicity as further described below.  
 
2.2 Proximal and distal tubular cell toxicity  
Renal tubular cells, especially proximal tubule cells, are vulnerable to the toxic effects of drugs. This 
is because their apical and basolateral transport systems facilitate extensive cellular uptake in their 
function of re-absorbing glomerular filtrate [20,23]. Thereby, proximal tubular cells are exposed to a 
high amount of circulating endogenous and exogenous compounds, including potential 
nephrotoxicants [12,20,23].  
 
Tubular cell toxicity may be elicited via different pathways which are induced by therapeutic agents 
such as aminoglycoside antibiotics, cisplatin and amphotericin B [12,25]. For instance, 
aminoglycosides are cationically charged and therefore attracted to the anionic phospholipid-rich 
brush border located at the proximal tubular apical membrane [76]. Accumulation of the 
aminoglycosides in tubular cells leads to the disruption of endosomal and lysosomal membrane and 
activation of intrinsic apoptotic pathway [45,75,77]. This includes impaired mitochondrial respiration 
and induction of oxidative stress through increased free radical levels within the cell. The kidney is 
particularly vulnerable to reactive oxygen species (ROS) damage [78]. Several nephrotoxic 
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compounds, e.g. cisplatin, immunosuppressant drugs, NSAIDS and aminoglycosides, exert their toxic 
effects due to excess ROS production, and depletion of the antioxidant defence mechanism [78]. 
 
Oxidative injury, inflammation, apoptosis, acute tubular necrosis as well as vasoconstriction have 
been associated with aminoglycosides as well as exposure to cisplatin [53,75]. The extent of 
exposure is suggested to determine whether apoptotic or necrotic cell death is induced. High 
concentrations of cisplatin in the millimolar range were reported to result in necrosis while 
concentrations in the micromolar range provoked apoptosis – via the intrinsic mitochondrial, 
extrinsic death receptor and ER-stress pathways [53].  
 
Experimental data suggested the intrinsic mitochondrial pathway to be the major pathway of 
cisplatin-induced apoptosis, likely to be induced by sulfhydryl group and mitochondrial glutathione 
(GSH) depletion [44]. Basolateral uptake by the organic cation transporter OCT2 has been 
demonstrated to be critical for cisplatin’s toxic response to be elicited in the kidney [53]. Also, 
different segments of the nephron demonstrate diverse sensitivities to cisplatin which did not 
appear to be due to differences in uptake characteristics but intracellular effects [79]. S1 cells 
derived from the early portion of the proximal tubule expressed a considerably lower amount of the 
anti-apoptotic protein BCL-XL than S3 cells derived from the late portion of the proximal tubule and 
distal convoluted tubular cells [79].  
 
The mitochondria of proximal tubular cells also appear to be key targets of nucleotide and 
nucleoside antiviral drugs stavudine and cidofovir [37]. Mitochondrial toxicity induced via 
mitochondrial DNA incorporation or mitochondrial DNA polymerase gamma inhibition may lead to 
tubular cell necrosis and acute renal failure [37]. 
 
Amphotericin B is also commonly associated with acute tubular necrosis which may be secondary to 
changes in haemodynamics and cell membrane permeability as described above, and resulting renal 
tubular acidosis and hypokalemia [74,75,80]. Unlike aminoglycosides and cisplatin, amphotericin B 
appears to elicit cellular toxicity predominantly in distal tubular regions as opposed to the proximal 
tubules [24,25,53].  
 
Another pathway leading to renal tubular necrosis is documented in an AOP related to 4-
aminophenol exposure whereby 4-aminophenol cysteine S-conjugates reach and get concentrated in 
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proximal tubules [36]. There, cysteine S-conjugates are metabolized to benzoquinoneimines which 
cause oxidative stress and necrotic tubular cell death [36]. 
 
2.3 Tubular, interstitial, tubulo-interstitial and glomerular nephritis  
Certain drugs, e.g. NSAIDs, antibiotics, loop and thiazide diuretics and proton pump inhibitors, 
induce kidney injury by producing inflammatory changes in the glomerulus, tubular cells and the 
interstitium, which can lead to fibrosis and renal scarring [12]. Many nephrologists consider these 
endpoints separately from each other due to differences in mechanisms leading to them. However, 
NSAID-induced nephritides may not be demarcated from each other but rather indicate a 
continuous spectrum of renal responses due to hypersensitivity against a drug influenced by the 
extent of drug exposure [81].  
 
Another study showed that in all forms of progressive glomerulonephritis, a major tubulo-interstitial 
infiltrate of immune-competent cells was present [82]. Moreover, the outcome of different forms of 
progressive glomerulonephritis was found to be determined by the presence and severity of tubulo-
interstitial changes rather than the degree of glomerular alteration [82]. For the purpose of this 
review, they will be discussed jointly.  
 
Drug-induced acute interstitial nephritis occurs as a result of dose-dependent renal tubular cell 
damage (including necrosis) or from an immune reaction directed against endogenous antigens in 
the kidney, and develops in an idiosyncratic, non-dose-dependent fashion [12,22,47,57,83]. In 
immune reaction induced cases, the usual symptoms of hypersensitivity, e.g. fever and rash, may be 
lacking [47,83]. An immunological response may be initiated through the deposition of a drug acting 
as a hapten or a circulating antibody-drug-based immune complex within the interstitium where it 
gets targeted by a, mostly cell-mediated, immune response [47,83]. As neutrophils and macrophages 
are attracted to the site, ROS and inflammation mediators are released leading to phagocytosis, 
tubular cell and glomerular injury [83,84]. Common drugs that induce acute interstitial nephritis 
include allopurinol, NSAIDs, antibiotics, loop and thiazide diuretics and proton pump inhibitors 
[12,22,25,75]. 
 
Chronic interstitial nephritis tends to be less drug-induced, however, has been reported with lithium, 
NSAIDs and aristolochic acid [12,20]. The main characteristics of this mechanism of nephrotoxicity 
are interstitial fibrosis and interstitial damage by far exceeding any glomerular effects, which may 
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include periglomerular fibrosis [22]. Also, tubular atrophy and an inflammatory infiltrate of 
lymphocytes, plasma cells and macrophages are observed [22].  
 
Glomerulonephritis has been reported to be induced by exposure to gold, interferon-α, 
cephalosporin, penicillin and pamidronate [12]. Its most common cause is IgA nephropathy, which is 
characterised by deposits of IgA-containing immune complexes in the kidney with proliferation of 
the glomerular mesangium [85]. Other forms of nephritis may be linked to autoimmune conditions, 
such as lupus nephritis. 
 
The AOP suggested for aspirin describes the pathway from the MIE of uncoupling/inhibiting 
mitochondrial oxidative phosphorylation to acute renal failure following acute tubular necrosis [29]. 
As adverse outcome or KE, interstitial nephritis is not included even though aspirin and other NSAIDs 
are recognised to induce this endpoint.  
 
2.4 Tubular obstruction 
Tubular obstruction may be caused through crystal deposition within the renal tubules. Certain 
drugs such as antibiotics (e.g. ampicillin, ciprofloxacin and sulphonamides), antivirals such as 
indinavir and acyclovir, light chain antibodies, methotrexate and polyethylene glycol produce 
insoluble crystals in the body [12,75,76,86]. These crystals may precipitate within the distal tubule, 
and obstruct urine flow. The likelihood of crystal precipitation depends on the amount of drug in the 
urine, the solubility of the drug and on the pH of the urine which is altered in conditions of renal 
tubular acidosis, metabolic acidosis or alkalosis [76,87]. With acidic urine (pH <5.5), crystal 
precipitation is increased for sulfonamides and methotrexate, and with alkaline urine (pH > 6.0), it 
increases for indinavir and ciprofloxacin [76].  
 
Renal hypoperfusion increases the chance of nephrotoxicity through this mechanism as renal 
tubules are exposed to high drug concentrations for longer than in a normally perfused kidney 
[20,87]. Low perfusion and a high intratubular drug concentration may lead to supersaturation 
within the distal tubules [88]. If the drug is administered at a high dose, mainly excreted via the 
kidney in its unchanged form and relatively insoluble in the urine, as in the case of acyclovir, crystal 
formation and intratubular precipitation is likely to occur [87].  
 
A recent report documented a new mode of cast formation induced by vancomycin [54] which had 
previously been associated with acute tubular necrosis and acute interstitial nephritis [12,48,89]. 
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These casts were described as atypical and non-crystalline consisting of vancomycin nanospheres 
entangled with uromodulin, an abundant protein in normal human urine, present in the tubular 
lumen and the Bowman's space suggesting tubular obstruction [54]. 
 
Little research appears to have been done to understand the formation of different shapes of 
crystals and their behaviour and pathomechanisms in different parts of the kidney [86]. 
 
2.5 Other mechanisms of nephrotoxicity  
Rhabdomyolysis and thrombotic microangiopathy have been discussed as additional mechanisms of 
nephrotoxicity elsewhere [12,57] but may also be regarded as systemic causes of nephrotoxicity. 
Rhabdomyolysis also causes tubular obstruction and refers to a syndrome where disintegration of 
striated muscle leads to release of muscular cell constituents, predominantly myoglobin and 
creatinine kinase, into the plasma [90,91]. Normally, myoglobin is loosely bound to plasma globulins 
and only small amounts reach urine. However, in rhabdomyolysis, large amounts of myoglobin are 
released; significantly more than can be bound by plasma globulins. Myoglobin is then filtered by 
glomeruli and reaches the tubules, leading to renal obstruction and renal dysfunction [90,91]. Drugs 
that cause rhabdomyolysis include certain statins, sedative hypnotics and antidepressants, alcohol 
and agents of abuse such as cocaine, heroin, ketamine, and methadone [90,91]. As nephrotoxicity is 
not primarily induced by these drugs this pathway is not considered as key mechanism. 
 
Thrombotic microangiopathy (TMA) is predominantly a vascular issue characterised by vessel wall 
thickening of arterioles or capillaries, and intraluminal platelet thrombosis, which leads to the 
obstruction of the vessel lumina. If these lesions prevail in the kidney, they are termed haemolytic 
uremic syndrome (HUS) and they are also, but less frequently, found in thrombotic 
thrombocytopenic purpura (TTP) which may be more associated with brain lesions [92,93]. Events 
leading to thrombotic microangiopathy are vascular injury - endothelial cells being the key target -, 
loss of endothelial thromboresistance, leukocyte adhesion to the damaged endothelium, 
complement consumption and enhanced vascular shear stress [92]. Drugs that cause nephrotoxicity 
through thrombotic microangiopathy include mitomycin C, clopidogrel, quinine, cyclosporine and 
tacrolimus [25,92,94,95]. The onset of general clinical manifestations such as microangiopathic 
haemolytic anaemia, and thrombocytopenia is often delayed [96]. TMA lesions have been reported 
in about 50 % of 128 patients diagnosed with IgA nephropathy [97], which is tightly linked to 
glomerulonephritis. 
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This, as well as a number of previously mentioned examples (e.g. tubular cell necrosis leading to 
interstitial nephritis in aspirin-induced nephrotoxicity) show very clearly that some of these 
mechanisms are interlinked as a number of substances elicit nephrotoxicity via more than one 
pathway. Mechanistic data describing molecular events initiating these toxicity pathways and effects 
further down the line are often lacking. Even fewer data are available which help to understand how 
these may be linked depending on dose and time. 
 
2.6 Site-Selective Nephrotoxic Injury  
Many drugs selectively cause nephrotoxicity through the above mechanisms on different segments 
of the nephron.   
 
2.6.1 Glomerular Injury  
The glomerulus is a primary site of chemical exposure and a number of drugs induce nephrotoxic 
effects there [74]. Glomerular ultrafiltration may be impaired by compounds acting on endothelial 
cells causing vasoconstriction of the renal arteriae (i.e. amphotericin B, gentamycin) or substances 
eliciting direct cytotoxic effect on glomerular epithelial cells (i.e. cyclosporine) [74]. By impairing 
GFR, the excretion of toxic metabolic waste is diminished. Glomerular injury may also result from 
circulating immune complexes getting trapped in the glomerulus and attracting neutrophils and 
macrophages which release ROS [74]. ROS greatly contribute to many glomerular diseases, including 
glomerulonephritis [98]. Heavy metals (e.g. HgCl2), volatile hydrocarbons and organic solvents cause 
glomerular injury via the above mechanism, and can also cause an increase in membrane 
permeability in the glomerulus. This will allow larger molecules e.g. albumin and γ-globulin, which 
are normally prevented from entry, to pass to the ultra-filtrate and be excreted along with the urine, 
thus causing proteinuria [74,84].  
 
 
2.6.2 Injury to Tubular Systems  
The most common site of drug-induced renal toxicity is the proximal tubule due to significant 
accumulation of chemicals in the tubule, contributed by the high reabsorption rates [74,84]. The 
proximal tubular cells have a leaky epithelium, which enhances the flux of compounds into proximal 
tubular cells, unlike the distant tubule characterised by a tight epithelium with high electrical 
resistance [74]. The proximal tubules are the critical, if not exclusive, site of transport for organic 
anions and cations, low-molecular-weight proteins and peptides, GSH conjugates, and heavy metals 
[74]. Drugs that preferentially affect the proximal tubules include aminoglycosides, β-lactams 
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(including cephalosporins), haloalkane-S-conjugates and α2μ-globulin bound chemicals i.e. cadmium, 
mercury and limonene [74,84,99]. For the cephalosporin antibiotic cephaloridine, the correlation 
between transport, accumulation, and nephrotoxicity is strong but this does not apply to other 
cephalosporins [74]. The intrinsic reactivity of the compound with molecular or subcellular targets 
within the proximal tubular cell is considered to be another decisive factor [74]. Chemical-induced 
injury is less common in the loop of Henle and the distal tubular system compared to the proximal 
tubules.  
 
2.6.3 Papillary Injury  
The renal papilla is also targeted for injury, mainly by excessive and abusive use of analgesics 
(analgesic nephropathy) [74,100]. This type of toxicity is characterised by renal papillary necrosis and 
chronic interstitial nephritis that leads to the onset of progressive kidney failure [100].  
 
2.7 Bladder Toxicity  
There is limited information on toxicity induced by compounds in the bladder. This could be because 
urine does not stay there for a long time. However, some carcinogenic compounds are known to 
target the bladder. One of the earliest examples of bladder cancer due to occupational exposure is 
2-napthylamine [74]. Other aromatic amines are also known to be carcinogenic to the bladder. 
Metabolism of these compounds in the kidney and bladder has been recognised to play a vital role in 
this toxicity pathway [74]. Similarly, a metabolite of both cytotoxic drugs cyclophosphamide  and 
ifosfamide, i.e. acrolein, is predominantly responsible for urothelial cell toxicity [101–104]. As stable 
urinary metabolite, acrolein reaches the bladder epithelial lining via the urine where toxicity is 
believed to be caused by ROS and nitric oxide (NO) production leading to lipid peroxidation, DNA 
damage and consequently necrotic cell death [103,104]. Other bladder related adverse events 
following drug exposure in humans include urolithiasis, blood in urine, and bladder disorders such as 
dysuria (i.e. painful urination), urinary incontinence, urinary retention  and polyuria [49]. However, 
these may be additional symptoms of systemic toxicity and not be adverse effects primarily 
observed in the bladder. 
 
Overall, each of these key mechanisms outlined above includes a number of sub-mechanisms which 
typically have not been defined conclusively on a molecular or level. An aspect which adds to the 
level of complexity already encountered when trying to establish models on these (sub-)mechanisms 
is the fact that some of these (sub-)mechanisms manifest jointly and therefore, appear to be 
interlinked, e.g. necrosis is part of the tubular cell toxicity mechanism but also appears to be present 
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in tubulo-interstitial nephritis. In Table 1, an AOP proposed by Lhasa Ltd. for the nephrotoxicity of 
NSAIDs is included, which denotes acute tubular necrosis and renal papillary necrosis as post-MIE 
KEs [29]. NSAIDs have been predominantly associated with interstitial nephritis and hemodynamic 
alteration [12,25] and not with tubular cell toxicity, which indicates that tubular necrosis is a pre-
stage of interstitial nephritis. 
 
In addition, the sensitivity and specificity of biomarkers, which have been used to a vast extent, e.g. 
serum creatinine and blood urea nitrogen, have been criticised over the last years [42,105,106]. In 
2008, the FDA designated seven biomarkers of nephrotoxicity for use in animals and, on a case-by-
case basis, in humans. These included urinary KIM-1, β2-microglobulin, cystatin C, clusterin, trefoil 
factor-3, albumin, and total protein. These markers and others (e.g., urinary NGAL, urinary IL-18, and 
the liver fatty acid binding protein (L-FABP)) have been studied in a range of conditions 
[31,39,42,106,107]. Certain biomarkers, which have been proposed, are specific to particular 
segments of the nephron but a signal in the proximal tubules may indicate various nephrotoxicity 
mechanisms. Knowledge is partly available suggesting that they may be attributed to a mechanism 
of toxicity [39,42,106] but a lot more research is needed to allow for a more refined mechanistic 
understanding.  
 
3.0 SOURCES OF DATA / INFORMATION ON KIDNEY TOXICITY SUITABLE FOR COMPUTATIONAL 
MODELLING 
Physiological, physico-chemical and toxicological data are the bedrock of the development of in silico 
models for toxicology. Some of the general issues related to data procurement for modelling 
purposes have been discussed elsewhere [108–113]. If the development of AOPs and multi-scale 
models is currently considered to be the panacea of 21st century toxicology, data spanning molecular 
to population levels are necessary to generate multi-scale models resembling the structure of AOPs. 
 
For the registration of many chemicals and pharmaceuticals, adverse effects to the kidney and 
bladder are currently assessed through traditional toxicological approaches, involving in vitro and in 
vivo animal studies [114]. However, a standardised test specifically designed to investigate a 
substance’s potential and mechanisms to elicit nephrotoxicity does not exist to date, as this would 
normally be assessed in repeat dose toxicity testing. In drug development, whilst safety 
pharmacology studies on the kidney are not part of the core required animal study battery, 
supplemental studies on the renal and urinary system may be performed if there is cause for 
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concern [115]. Furthermore, clinical studies of drug compounds in humans cover endpoints related 
to renal toxicity but their efficacy to assess this pathology adequately has been challenged by the 
high number of drug-induced acute renal failure cases in critically ill and chronic kidney disease 
patients.  
A list of over 250 potential nephrotoxicants has been compiled including, where available, 
information on a putative or confirmed MIE and AOP, using current knowledge from the literature 
[12,20,25,28–30,34–39,44–49,53,54,73,86,89,101–104,116–188]. This list can be accessed via the 
supplemental information and provides a comprehensive, publicly available compilation of 
nephrotoxicity data. For modelling purposes, this list needs to be enriched with chemistry-, activity- 
and toxicity-related data. There are over 400 databases available of which over 200 are publicly 
available geared towards chemistry, toxicology, Absorption, Distribution, Metabolism and Excretion 
(ADME) properties, as well as molecular biology (-omics) and pathways, which may be accessed for 
model generation. The following review of databases sheds some light on how well publicly available 
data may inform future nephrotoxicity modelling. This review is by no means complete but covers 
the most significant resources currently available for modelling. Searches were performed at 
timepoints recorded in the references’ section. 
 
In reviewing data sources, it must be remembered that several different types of data and data 
compilations are required and ideally these should be suitable for modelling. Traditional QSAR 
modelling requires datasets of consistent information for a group of compounds, this could include 
the presence or absence of nephrotoxicity or quantitative estimates of potency – providing the data 
have been measured in a consistent manner (i.e. the same test protocol). Read-across can be 
attempted on smaller data sets – even a one-to-one approach using a potentially wider variety of 
data – non-standard data from multiple and different sources can be used to build up a weight of 
evidence. However, physiologically based kinetic (PBK) and multiscale models focus on several 
parameters (clearance and absorption rates, volume of distribution, partition coefficient) for a single 
compound. Thus, there may be different uses of the data resources covered in this section.  
 
3.1 Chemical and biological data 
In order to relate adverse effects to structural components, properties such as solubility, receptor 
binding, or enzyme inhibition, data on chemical structures, physico-chemical and functional 
properties and potency are needed. 
 
22 
 
A reliable source of information on chemical structures is ChemIDplus Advanced [189, 
https://chem.nlm.nih.gov/chemidplus/]. A search in the toxicity field for “kidney, ureter, and 
bladder” effects revealed 139,289 records for 1,352 structures. However, for each record, it is not 
immediately obvious why a compound is associated with the above mentioned endpoint. 
ChemIDplus is based on more than 100 sources, including the Comparative Toxicogenomics 
Database (CTD), the Hazardous Substances Data Bank (HSDB®), the Integrated Risk Information 
System (IRIS), and the International Toxicity Estimates for Risk (ITER) [190,191] such that information 
– which is often replicated many times, may be drawn from any of these resources.  
 
Other reliable sources of chemical information include, but are not limited to, the following. 
Chemical structures and physico-chemical properties can be sourced per chemical and downloaded 
from the U.S. EPA Chemistry Dashboard [192, https://comptox.epa.gov/dashboard/]. Elsewhere, 
ChEMBL [193,194, https://www.ebi.ac.uk/chembl/] is a database of bioactive compounds which 
allows access to compound-specific ADME and bioactivity information (e.g. binding measurements, 
functional assay data) including specifics on the mechanism of action, and (non-)molecular targets. 
Pharmacological, biological and chemical data of pharmaceuticals and other substances can be 
found in DrugBank [195,196, https://www.drugbank.ca/]. ChEMBL and DrugBank data may be 
searched for jointly and in parallel to information from other databases through UniChem [197,198, 
https://www.ebi.ac.uk/unichem/]. Compound-specific physico-chemical properties may also be 
sourced from PubChem [199,200, https://pubchem.ncbi.nlm.nih.gov/]. The Online Chemical 
Modelling Environment [201,202, https://ochem.eu/home/show.do] offers pharmacological and 
physico-chemical data along with an interface for calculating and selecting a number of molecular 
descriptors.  
 
3.2 Molecular Biology (-Omics) Data 
High-throughput biology data including genomics, proteomics, transcriptomics and metabolomics in 
various tissues have been used to identify relevant molecular mechanisms, toxicity pathways, and 
biomarkers. A number of kidney tissue specific databases discussed below have been established to 
provide gene, peptide and protein expression data.  
 
The Renal Gene Expression Database (RGED) [203,204, http://rged.wall-eva.net/] and NephroseqTM 
[205, https://www.nephroseq.org/resource/login.html] are platforms providing free access to gene 
expression information in specific renal diseases. Within RGED, only searches by gene are possible 
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while on NephroseqTM a more refined analysis may be done on molecular characteristics of disease 
phenotypes, markers of disease progression and to a very limited extent treatment response.  
 
Data on protein expression in healthy and diseased kidney tissue and urine can be accessed through 
the Human Kidney & Urine Proteome Project (HKUPP) [206, http://www.hkupp.org/index.htm]. 
Search options for data established in the glomerulus, proximal and distal tubules and the collecting 
ducts from three samples of three kidney cancer patients (two males and one female, aged between 
71 and 77) are under construction at the time of this review.  
 
The Urinary Peptidomics and Peak-maps database (UPdb) [207,208, http://www.padb.org/updb/] 
gathers information on urinary peptides modified in disease. Of relevance to nephrotoxicity 
modelling are entries related to exposure to mixtures of arsenic and lead [sourced from 209], 
membranous glomerulonephritis [sourced from 210], IgA nephropathy [sourced from 211] and 
healthy volunteers as controls [various sources including 212,213]. 
 
Via the Kidney & Urinary Pathway Knowledge Base (KUPKB) [214,215, http://www.kupkb.org/#tab0], 
a collection of human and animal derived urine and kidney tissue based miRNA, mRNA, protein and 
metabolite expression data can be accessed. KUPKB can be searched for information related to 
specific locations, cells or fluids within the kidney and bladder or a specific condition or disease 
model. The extent of molecular expression is reported as ‘up’, ‘down’, ‘present’, ‘absent’, ‘medium’ 
and ‘strong’, which requires accessing the original data source if numerical measures are necessary 
for further analysis. 
 
Sources of genomics data with a clear focus on toxicity endpoints are the Comparative 
Toxicogenomics Database (CTD) [216,217, http://ctdbase.org/] and the ToxicoGenomics Project-
Genomics Assisted Toxicity Evaluation system (Open TG-GATEs) [218,219, 
http://toxico.nibiohn.go.jp/english/]. A search of the CTD for the keyword “kidney” in all sections 
shows matches with 3 chemicals, 291 genes, 68 gene ontologies, 51 diseases, but 0 pathways. The 
Open TG-GATEs may be browsed for chemicals or kidney pathologies, which may not be 
unambiguously assigned to one of the key toxicity mechanisms discussed in more detail below. 
 
3.3 In vitro 
In vitro data in this section include information from receptor binding and single cell assays up to the 
sophistication of 3D tissue cultures, bioreactors and organoids. The cheaper and more rapid the 
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assay, the greater is the likelihood of a proliferation of data for modelling. A major platform 
providing high-throughput in vitro screening data is the U.S. Environmental Protection Agency’s 
(EPA) ToxCastTM programme. On the ToxCastTM Dashboard website [220, 
https://actor.epa.gov/dashboard/], when the database was filtered for assays on the kidney, data 
for 70 assays are shown to be present (according to assay component endpoint names), 1 of which is 
based on rat kidney membranes, 2 on pig tissues, and 67 on human cell lines. These assays vary to a 
great extent, for instance in terms of their statistics (e.g. the total number of samples tested, and 
percent of active samples) or their biological process target (e.g. regulation of catalytic activity, 
receptor binding, or protein stabilisation). An overview of these assays can be found in Appendix A 
contained in the supplementary information. When assessing whether a substance is active in an 
assay, the effect concentrations need to be compared to the compound’s burst concentration which 
denotes a cytotoxic effect at that level [221]. The utility of in vitro ToxCastTM data has been widely 
debated [222–229], and a more detailed analysis is required to confirm to which extent these targets 
are related to currently known KEs of nephrotoxicity pathways. In addition to kidney tissue assays, 
the ToxCastTM database contains a broad variety of assays, which may be relevant to in silico models 
for nephrotoxicity, e.g. cytotoxicity or oxidative stress. Lin and Will [120] found that HepG2 
(hepatocellular carcinoma), H9c2 (embryonic myocardium), and NRK-52E (kidney proximal tubule) 
cells equally serve to screen for general, non-organ-specific cytotoxicity. Therefore, liver, heart or 
other tissue cells may be suitable for the prediction of nephrotoxicity endpoints. 
 
The Hazardous Substances Data Bank (HSDB®) [230, 
https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm] contains 393 records for the search term 
“nephrotoxic*” and 2865 records for “kidney”. When selecting “download records”, general, i.e. 
non-nephrotoxicity-specific, in vitro and in vivo animal toxicity, metabolism and pharmacokinetic 
data may be downloaded as txt file. Renal transporter expression levels, their localisation, substrates 
and inhibitors may be found on the UCSF-FDA TransPortal [231,232, 
http://transportal.compbio.ucsf.edu/]. In vitro models of particular interest due to their enhanced 
complexity and physiological relevance are spheroid and kidney slice assays. Whilst research with 
spheroids has been conducted to investigate kidney disease and treatment options [233–235], no or 
few relevant toxicological studies with kidney spheroids were identified. Conversely, toxicity and 
kinetic studies have been performed in animal and human kidney slices for years [236–239] but no 
database was identified, in which kidney slice data can specifically be searched for. 
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3.4 In vivo  
In vivo data provide valuable insights into mechanistic pathways of kidney and bladder toxicants and 
the most meaningful are likely to be gained from long-term, repeated dose, low concentration tests. 
As with all endpoints, the relevance of inter-species differences must, however, be appreciated if 
there is an expectation to extrapolate animal data to humans. For instance, amongst many well 
known issues, rat data cannot be used to establish dose-response relationships of effects dependent 
on proximal tubular transporter activity as significant differences in transporter clearance between 
humans and rats exist [56,240]. 
 
From the U.S. EPA’s Toxicity Reference Database (ToxRefDB), lowest effect levels (LELs) can be 
retrieved on 30 kidney related toxicity endpoints and 13 urinary bladder related toxicity endpoints 
[126]. Appendix B contained in the supplementary information lists all these endpoints. However, 
only 12 compounds were identified with the lowest LEL associated with urinary or kidney endpoints. 
Other compounds, for which urinary or kidney related LELs were recorded, had LELs associated with 
other toxicity endpoints lower than those associated with nephrotoxicity. 
 
As mentioned above, in vitro and in vivo animal toxicity, metabolism and pharmacokinetic data may 
be downloaded in txt file format from the Hazardous Substances Data Bank (HSDB®). In addition, the 
COSMOS DB [241,242, http://www.cosmostox.eu/what/COSMOSdb/] contains in vivo toxicity data 
including highest no effect level (HNEL) and lowest effect level (LEL) information. When performing a 
database search with a toxicity query for the endpoint “chronic toxicity” and the site “kidney” for all 
species/strains, routes of exposure, effects, assays and both sexes, 68 hits, i.e. compounds inducing 
nephrotoxic effects in animals, are presented. For the vast majority of these substances, i.e. 53, one 
study was recorded; for 13 compounds, 2 studies were recorded and for two substances 4 and 5 
studies were presented. A toxicity query for the endpoints “special toxicology study” and 
“subchronic toxicity” and the site “kidney”, resulted in 202 hits with mostly 1 and up to 11 studies 
recorded. More specific sites can be queried for, e.g. “kidney > renal tubule > epithelial” or “kidney > 
interstitial cells” which facilitates the search for mechanism-specific toxicity information. 
 
Fraunhofer ITEM created a commercially accessible database on high-quality subacute to chronic 
toxicity studies called RepDose [243]. A subset of approximately 200 subacute studies is made 
available for free on http://fraunhofer-repdose.de/ [244]. The database query for “kidney” as 
organ/target parameter found 113 entries. However, these data were not displayed and query 
conditions needed to be restricted in order for results to be displayed. After specifying the effect 
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“nephropathy”, 8 entries were found and displayed, i.e. the CAS numbers and names of 8 
substances. 9 entries were identified for “kidney” and “necrosis”. These results indicate that 
RepDose may be used to identify potential nephrotoxicants but does not provide in vivo data for 
further analysis. 
 
A Urinary Protein Biomarker (UPB) database in Chinese language may be accessed via 
http://bmicc.cn/web/share/search/hupd [245]. 
 
3.5 Human data - clinical and post-marketing  
For known nephrotoxicants, clinical and post-marketing data as well as case reports in the public 
domain give insight into toxic effects observed in humans at a given dose. Most valuable are clinical 
data as doses and effects are clearly recorded. With the use of more refined biomarkers, more 
information will be gained from these studies in the future.  
 
From the Hazardous Substances Data Bank (HSDB®), epidemiological data and case reports can be 
retrieved in the form of a txt file. However, data gathered from post-marketing reports often do not 
include (reliable) information on the dose taken by the patient. If dosing information is available – as 
in the case of clinical studies –, it may be challenging to compare dose-response data of 
investigations which adhered to differing classifications as different definitions and criteria to classify 
the severity of certain nephropathy outcomes exist [24]. 
 
The U.S. National Library of Medicine provides clinical trial data on ClinicalTrials.gov [246, 
https://clinicaltrials.gov/]. Queries can be performed for substances, however, not for adverse 
events. Dosing information and adverse events are published for completed studies but these data 
do not appear in the downloadable record. 
 
The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), formerly 
AERS, can be accessed via http://www.fdable.com/basic_query/aers [247] and was searched for 
kidney related specific event descriptions such as kidney fibrosis or focal glomerulonephritis, or renal 
failure in general. Among the information given are the primary suspect drug, patient outcome, age 
and gender of the patient. Adverse event data existing in FAERS may have been submitted to the 
FDA by drug and therapeutic biological product manufacturers, healthcare professionals or 
consumers. When using these data, their limitations need to be taken into account, i.e. no proof of a 
causal relationship between exposure to a drug and adverse event, duplicate reports and inherent 
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incompleteness of the database [248]. Ursem et al. [49] grouped adverse effects reported to FDA’s 
previously established Spontaneous Reporting System (SRS) and the AERS into a renal disorder 
cluster, a nephropathies cluster, a kidney function tests cluster and a bladder disorder cluster and 
through a weight of evidence approach identified substances most likely to induce these cluster 
endpoints.   
 
When accessing EudraVigilance, the European database of suspected adverse drug reaction reports 
[249, http://www.adrreports.eu/], the number of individual cases of adverse events following the 
administration of a drug can be queried . Searches are performed for drug products or substances, 
and occurrences on “Renal and urinary disorders” per age group may be retrieved on the section 
“Number of Individual Cases by Reaction Groups”. Displayed graphs clearly show whether renal and 
urinary disorders are predominant adverse events for a particular drug but no information are 
immediately evident on comorbidities of the patient population and exact doses administered. 
 
3.6 Relevance of existing sources to in silico modelling 
Section 3 demonstrates considerable resources for in silico modelling of nephrotoxicity. However, no 
comprehensive database exists with multi-scale information that can be used for in silico 
nephrotoxicity model development. Databases focussing on kidney tissue data (predominantly in the 
omics field) are principally geared towards the diagnostics, understanding pathological pathways 
and treatment of kidney disease as opposed to chemical induced kidney toxicity. In order to 
establish reliable dose-response relationships, in vivo data are highly desirable. The AOP paradigm 
and means of organising information provides a possible structure to multi-scale models. Table 2 
summarises which type of data informs the various parts of an AOP-structured multi-scale in silico 
model. The use of (novel and existing) data sources to support in silico modelling is taken up in more 
detail in Section 5 (Expert Opinion). 
 
Table 2: Data informing all stages of a multi-scale in silico model 
Level Mechanism Cellular Apical toxicity Human toxicity 
Examples of 
data and what 
they may be 
used for 
Molecular biology 
(-omics) data on 
MIEs or, if 
unavailable, other 
molecular 
mechanisms 
In vitro data on 
receptor binding, 
cellular toxicity, 
cellular uptake, 
enzymatic 
activity 
In vivo data on 
mechanistic 
pathways and 
their association 
with biomarkers 
Clinical trials / 
post-marketing 
data on human-
specific effects, 
dose-response-
relationships, 
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sensitivity/ 
specificity of 
biomarkers 
Comparative 
databases 
RGED, 
NephroseqTM, 
HKUPP, UPdb, 
KUPKB, CTD 
ToxCastTM, 
HSDB®, UCSF-
FDA TransPortal 
ToxRefDB, 
COSMOS DB, 
RepDose, UPB 
HSDB®, 
ClinicalTrials.gov, 
FAERS, 
EudraVigilance 
 
 
 
4.0 (Q)SARs AND MATHEMATICAL MODELS TO SIMULATE KINETICS AND TOXICITY: CURRENT 
STATE-OF-THE-ART AND NEXT STEPS  
As noted above, as part of the hazard identification process it is important to be able to predict 
accurately human nephrotoxicity. The traditional approach for determining safety and toxicity of 
drug candidates is through histopathological observation from in vivo animal studies [42,250–252] 
or, more recently, from targeted in vitro testing. However, in recent decades, alternative methods 
for hazard assessment without the need for testing, such as in silico approaches, have been 
increasingly applied, particularly for the prioritisation of data requirements and identification of 
chemicals that may require more detailed risk assessment. Computational toxicology also allows for 
the possibility to link molecular pathways to cellular processes and a toxicity endpoint at the tissue 
level.  
 
In this review, two fundamentally different in silico toxicology methods are discussed, i.e. chemistry 
driven (Q)SARs and physiologically-based mathematical models. The former identify relationships 
between a structure of a molecule and its toxicity while the latter simulate the physiologically-based 
toxicokinetics of a compound which allows predictions of whether (and which) effects may be 
elicited. 
 
4.1 (Q)SAR models 
In silico methods include chemical structure driven SARs and physico-chemical property and 
molecular descriptor driven QSARs to predict and profile toxicities [253]. These provide a correlation 
between an effect, often a regulatory endpoint, and properties of a molecule. SARs are often 
developed into SAs which relate qualitatively a particular biological effect or toxicity endpoint to a 
specific fragment of a molecule [253,254]. SAs have been developed to aid identification of 
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chemicals that can bind to proteins [255,256] or induce mitochondrial toxicity [257]. These chemical-
biological interactions have been identified as potential mechanisms of eliciting renal (and other) 
toxicities. SAs associated with potential toxicity have been compiled and encoded into predictive 
software, for example ToxAlerts – a freely available screening tool available within the online 
chemical modelling environment (https://ochem.eu/home/show.do) and the alerts incorporated in 
DEREK Nexus (Lhasa Ltd, Leeds). For certain compounds, toxicity may be elicited via the formation of 
reactive metabolites, rather than inherent toxicity of the parent molecule. Claesson and Minidis 
[258] have collated and organised publicly available SAs that may be associated with reactive 
metabolite formation and idiosyncratic adverse drug reactions. QSARs provide a statistical 
relationship between the structure of a chemical, its physico-chemical properties and its effects 
[253]. QSAR models have demonstrated good predictive ability, especially for simple end points 
[250,259].  
 
The primary objective of (Q)SARs is to distinguish between toxicologically inactive or active 
compounds and, where possible, provide a quantitative estimate of potency or relative effect. 
Frequently, several mechanisms elicit the same toxicological endpoint. Thus, predictive models must 
be able to distinguish all fragments corresponding to all relevant mechanisms from inactive 
fragments. Two main types of commercial systems have been developed: knowledge-based systems 
(e.g, DEREK Nexus and OncoLogic) and statistically-based systems (e.g. TOPKAT and MultiCASE) [260] 
although there is a trend for hybrid systems which may link a quantitative estimate to an SA e.g. 
ChemTunes [261, https://www.mn-am.com/products/chemtunes]. Knowledge-based systems use 
rules derived from human expert opinion and interpretation of toxicology data to define the 
relationship between a structure and its activity. These rules are utilised to predict potential toxicity 
of known and novel chemical compounds. Statistically-based systems use calculated parameters and 
statistical methods to derive mathematical relationships for a training set of compounds [260].  
 
(Q)SAR models developed so far for nephrotoxicity, specifically, are summarised in Table 3 with 
details on the exact endpoint, number and type of molecules the model is based on, the method 
used, results, as well as strengths and weaknesses of the approach below.  
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Table 3: Summary of (Q)SAR models associated with kidney and bladder toxicity 
Endpoint 
Number and type 
of molecules 
Method  Results: QSAR / SAR Strengths Weaknesses 
Model 
reference 
Rat nephrotoxicity 
16 derivatives or 
1,2- and 1,4-
naphthoquinones 
SA 
Whilst preliminary SAs were 
presented, no definitive SAs 
were defined 
Changes in the extent of 
nephrotoxicity due to structural 
alterations of 2-hydroxy-1,4-
naphthoquinone and 4-amino-1,2,-
naphthoquinone were determined  
No SAs identified; mechanism of 
toxicity was not determined, small 
applicability domain 
Munday 
et al. 
[262] 
Toxicity to the kidney 
and urinary tract based 
on repeat-dose toxicity 
study-derived NOAELs 
and LOAELs in rats 
503 chemicals 
SAs based on 
likelihood ratio 
and percentage 
of true positives 
6 SAs 
 
Mechanistic information available 
for some SAs based on literature 
Mode of action data is generally 
basic and not available for all SAs 
Pizzo et 
al. [263] 
Nephrotoxicity 
Confidential 
database 
amalgamated from 
multiple industries 
Knowledge-based 
expert system 
using SARs 
SAs 
SAs are in some cases associated 
with mechanistic information 
Certain substances, e.g. inorganic 
compounds, cannot be analysed 
Derek 
Nexus 
[264] 
"Nephrotoxicity" (NT) 
and subcategory 
endpoints "kidney 
necrosis" (KN), "kidney 
relative weight gain" 
(KWG) and "nephron 
injury" (NI) 
Training set:  
NT: 847; KN: 221; 
KWG: 240; NI: 598; 
Test set: 
NT: 154; KN: 42; 
KWG: 49; NI: 109 
QSAR models and 
toxicophores 
192 SAs for all kidney-
related endpoints 
QSAR models demonstrate good 
performance overall; QSARs and 
toxicophores were based on the 
same compound sets; 
comparatively broad applicability 
domain 
Endpoints "kidney weight gain", 
"nephron injury" and 
"nephrotoxicity" cannot be 
specifically attributed to a 
nephrotoxicity mechanism 
Myshkin 
et al. 
[265] 
Competency of rat liver 
MGST1 to catalyse 
9 haloalkenes; as 
no or low GSH 
QSAR model 
Linear relationship between 
ELUMO values between -1.14 
Findings may be valuable for 
understanding and predicting the 
Small applicability domain; linear 
relationship does not exist for 
Jolivette 
and 
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bioactivation of 
molecules to toxic 
metabolites 
transferase activity 
was detected for 4 
molecules, QSAR 
was investigated 
for 5 haloalkenes 
to -0.73 eV and the natural 
logarithms of activities for 
GSH conjugation reaction 
route of metabolism of 
haloalkenes and their associated 
toxicities; haloalkenes are widely 
used, so results may help to make 
chemical design amendments for 
many applications 
ELUMO values outside of -1.14 to -
0.73 eV range 
Anders 
[266] 
α2μ-globulin 
nephropathy in male rats  
Not specifically 
known, dataset 
includes 43 43 
aliphatic and 
alicyclic 
hydrocarbon 
structures 
Combination of 
two QSARs based 
on multiple 
regression 
analysis and 
principal 
component 
analysis 
Incorporating electro-
negativity properties, size 
and shape dependent fit of 
binding site: log IC50 = 4.525 
(-ve charge density) - 0.044 
(Mol Vol) = 2.545; r2 = 
0.836; cross-validated r2 = 
0.601 
To identify whether kidney lesions 
observed in in vivo studies in male 
rats may be caused by this 
pathway 
Mechanism specific to male rats, not 
relevant to humans; applicability 
domain was not discussed 
Barratt 
[99] 
Tubular necrosis, 
interstitial nephritis and 
tubulo-interstitial 
nephritis in humans 
Parent compounds 
(251 
nephrotoxicants 
and 387 non-
nephrotoxicants) 
and their urinary 
metabolites (307 
nephrotoxicants 
and 233 non-
nephrotoxicants) 
Binary 
classification 
QSAR models 
Eight substructure 
fragments common to both 
datasets for all of the above 
three nephrotoxicity 
mechanisms 
Metabolism-dependent toxicity; 
may help to understand to which 
extent and how the three 
mechanisms are interlinked; 
consideration of metabolites; 
based on human data  
Model could not be accessed; data 
on molecules were not published 
Lee et al. 
[252] 
"Nephropathies", "acute 
renal disorders", 
"bladder disorders", 
Not specifically 
known 
QSAR models 
Four QSAR programmes 
were used, i.e. MC4PC, 
BioEpisteme, MDL QSAR 
Based on human data and four 
QSAR programmes with different 
prediction programmes; high 
Non-uniform reporting of adverse 
events post marketing approval; 
patient population with multi-drug 
Matthews 
et al. 
[267] 
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"blood in urine", 
"urolithiases" and 
"kidney function tests" in 
humans 
and Leadscope Predictive 
Data Miner 
applicability domain among 
pharmaceuticals 
exposure and co-morbidities; certain 
drugs (inorganic chemicals, high 
molecular weight substances (>5000 
Da), organometallic chemicals, gases) 
and industrial chemicals not covered; 
while specificity was set at > 80 %, 
sensitivity was in some cases very 
low (< 20 %) 
Pathways associated 
with renal tubular 
degeneration based on 
rat kidney data 
88 chemicals, 
including 22 
molecules inducing 
renal tubular 
degeneration 
QSAR linking 
physico-chemical 
features to 
transcriptional 
activity 
Nephrotoxic substances are 
associated with high 
polarisability, low 
electronegativity, and low 
symmetry 
Multi-scale modelling linking 
chemical data to gene expression 
and a nephropathological outcome 
Focus on agents which directly  act 
on proximal tubular cells; 
applicability domain is unclear 
Antczak 
et al. 
[268] 
Renal adverse drug 
reactions 
507 drugs (126 
active, 208 
inactive, 173 of 
undetermined 
activity) 
QSAR based on 
decision tree 
inference analysis 
using CART and 
CHAID 
CART model highlights 
influence of amine 
functions, sulphur, and 
carboaromatic ring 
structures. For substances 
less toxic to the kidney, 
CHAID model found few 
aromatic atoms (<19), a 
basic pKa <10.71, van der 
Waals surface area <1,014.5 
Å2, and logP values >2.43 
Both models performed well, with 
CART and CHAID model CCRs of 
88.6 and 84.7%, respectively; 
based on human data 
Only valid for drug-like molecules, 
not necessarily suitable for other 
compounds 
Hammann 
et al. 
[269] 
 
Urinary tract toxicity 
(LD50 in kidney, ureter, 
258 organic 
compounds 
Classification and 
regression QSAR 
models based on 
SVMBoost based on the RBF 
kernel accomplishes the 
best quantitative and 
 
Reliable prediction is achieved by 
both regression and classification 
Adequacy of mouse intraperitoneal 
LD50 values as endpoint is unclear 
Lei et al. 
[270] 
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and bladder) in mice eight machine 
learning 
approaches 
qualitative predictions for 
the test set (MCC of 0.787, 
AUC of 0.893, sensitivity of 
89.6%, specificity of 94.1%, 
and global accuracy of 
90.8%) 
models based on the SVMBoost 
approach; all tested chemicals are 
within the application domain 
coverage 
Abbreviations: CART = classification and regression tree; CHAID = chi-squared automatic interaction detector; CCRs = corrected classification rates; LD50 = dose which is lethal to half of total 
treated animals
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More detailed information on these QSAR models are provided in Appendix C [87,99,252,262–276] 
of the supplementary information. It is also noted that QSAR models have been developed to predict 
renal clearance, which were examined in more detail elsewhere [56]. 
 
4.2 Mathematical (mechanism-based) models 
In contrast to (Q)SAR methods, mathematical mechanistic and physiologically-based models can be 
used to simulate the kinetics of a compound through the body and at the site of toxicity. As a vast 
number and quantity of substances are moving through the kidney, and considering the key 
principle of toxicology – the dose makes the poison (Paracelsus) – an understanding of a 
compound’s movement and its potential for accumulation at specific sections of the kidney are 
considered critical. In section 2, accumulation is described to play an important role in certain 
nephrotoxicity pathways. 
 
Some of the early mechanistic models to predict renal clearance include passive reabsorption and 
urine flow [277], which are supplemented by protein binding and glomerular filtration [278–281] 
and active secretion [282–285]. Subsequently, Felmlee et al. [286] develop a hybrid physiological, 
mechanistic toxicokinetic (TK) model to simulate the saturable renal reabsorption and capacity-
limited metabolic clearance of γ-hydroxybutyric acid (GHB) with two ultrafiltrate compartments 
representing the proximal and distal tubules, and active renal reabsorption from the first ultrafiltrate 
compartment only. Two (fast and slow) tissue distribution compartments best described plasma 
GHB concentration. As in earlier models, urine flow and the glomerular filtration rate (GFR) are 
included, while passive reabsorption, active secretion and protein binding are not incorporated, as 
they do not seem to play a vital role in the renal elimination of GHB.  
 
Felmlee et al. [287] extended their work by adding active tubular secretion to their investigations 
into active tubular reabsorption. The authors evaluate previously published compartmental and 
semi-physiologically based models pharmacokinetic (PK) models of active tubular reabsorption and 
secretion. By merging some of these approaches, they establish a universal mechanistic model 
predicting renal clearance of substances being subject to active secretion, active reabsorption or 
both of these processes, for a broad applicability domain. Metabolism and passive reabsorption are 
not considered in this study. 
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Independent of models to predict the kinetics of therapeutic or other chemical compounds, Layton 
[288] review mathematical models to describe physiological and pathophysiological processes of the 
kidney. These processes include the regulation of glomerular filtration and renal blood flow by the 
tubulo-glomerular feedback and myogenic mechanism, epithelial and renal oxygen transport, and 
the urine concentrating mechanism. A mechanistic understanding of intrarenal oxygen transport and 
consumption may be a valuable component to add to a toxicokinetics related kidney model as renal 
tissue hypoxia has been argued to drive kidney disease [289,290]. 
 
One of the most detailed mechanistic kidney models is Mech KiM which predicts renal elimination 
by accounting for glomerular filtration, active and passive reabsorption, active and passive secretion, 
renal metabolism, bypass of parts of the renal blood flow, transporter scaling factors and population 
variability [56]. The nephron is divided into eight segments representing the glomerulus, proximal 
and distal tubules, Loop of Henle and collecting ducts. Each segment encompasses three 
compartments, illustrating the blood space, tubular fluid and cellular mass. While applying the law of 
conservation of mass, ordinary differential equations describe the movement of a compound 
between compartments. Limitations of this model revolve around missing data, e.g. on proximal 
tubular cells per gram of kidney (PTCPGK) and absolute renal transporter abundances at different 
parts of the nephron.  
 
Overall, there are limited computational toxicity methods available for more complex endpoints 
such as nephrotoxicity – likely to be due to the highly complex mechanisms of toxicity [250,252,262] 
or limitations of the availability of structured, high quality data. Most models presented above focus 
only on very small groups of compounds, meaning that the applicability domain is limited to the 
specific groups of compounds used to develop the model. Some models, i.e. Lee et al. [252], 
Myshkin et al. [265], Matthews et al. [267] and DEREK, have been generated on the basis of larger 
datasets or commercial software which are not publicly available. Mechanistic models to compute 
the biokinetics of compounds have limitations due to missing data and are in part not publically 
available either. To date, there is no multi-scale nephrotoxicity model available which may be due to 
the lack of high quality data connecting molecular and cellular mechanisms to tissue and organ 
processes leading to an adverse individual outcome while understanding uncertainties related to 
inter-individual variability. In the following section, knowledge of the main mechanisms of 
nephrotoxicity as well as missing information vital to modelling purposes will be summarised. 
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5.0 EXPERT OPINION 
As a major organ of elimination and therefore subject to high exposure of compounds, the kidney 
has been recognised as a significant target for drug and chemical induced toxicity. This, and the lack 
of comprehensive test data for many chemicals in sectors other than pharma, clearly show that 
screening for, and assessment of, nephrotoxicity is an important area for improvement. In silico 
methods have been evolving steadily and have the potential to contribute immensely to the field of 
toxicology in general. Although several in silico models currently exist for other organ-level toxicities 
e.g. hepatotoxicity, this review has found that in silico models associated with nephrotoxicity are 
very limited, and even fewer differentiate between key mechanisms or incorporate mechanistic 
data. 
 
In order to improve and expedite the development of in silico models for kidney toxicity, at least 
three – highly interrelated - problems have to be overcome. These are: 
 
i) The identification and definition of effects to the kidney that may be brought about by 
chemical exposure. 
ii) A full description of relevant mechanisms of toxic action relevant to kidney toxicity. 
iii) Access to appropriate data ranging from in vivo through to molecular responses.  
 
The identification of effects to the kidney requires an ontology to be developed that will unify 
existing knowledge. This may grow out of networked AOPs although would benefit from a 
systematic evaluation of current knowledge and effects. Once an ontology has been developed it 
would be the ideal starting point for a framework to underpin data and models. With regard to the 
data from which to develop the models, no assay exists which is specifically targeted towards renal 
toxicity endpoints and interspecies variability between rats and humans is known to be relevant for 
certain pathways (i.e. certain transporter-driven and α2μ-globulin related nephrotoxicity). 
Therefore, the usefulness of in vivo data in the area needs to be assessed carefully. Human and in 
vitro assay data are widely available but need to be utilised with care due to challenges related to 
relevance for one of the discussed nephrotoxicity mechanisms, comparability of studies, pre-existing 
comorbidities in patient populations and other factors related to data interpretation. A strategic for 
utilising existing data at different levels of AOPs is shown in Table 2. Such an approach to organising 
information, as defined within an appropriate ontology, may prove to be an extremely effective, and 
not requiring full testing of every compound, solution to model development. In addition, as the lack 
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of readily available data is considered to be a key limiting factor when it comes to the generation of 
future computational models in this field, therefore the following recommendations may help to 
drive future modelling efforts forward: 
 
(i) Improved understanding of how novel, recently proposed, biomarkers relate to the mechanisms 
of nephrotoxicity, discussed earlier, and how they are related quantitatively to each other. This may 
result in alternative sources of data and could be facilitated by statistical approaches.  
(ii) A global review of the quality of currently available kidney toxicity data is needed as well as an 
assessment of how these data relate to each other (e.g. cellular vs. tissue vs. organ-level effects). 
Information would be leveraged more readily if databases allowed for searches on both compounds 
and mechanistic data (including dosing information) enabling discrimination between the various 
nephrotoxicity endpoints.  
(iii) Generation of more AOPs for nephrotoxicity with MIE and KE related data being searchable in a 
central database linked to respective mechanistic toxicological data would also assist the 
development of more computational models.  
 
The linkages between in silico models have been defined clearly, with data related to the MIE being 
able to contribute to the development of a model [10]. While a binary interpretation of an MIE may 
be used to understand whether a substance has the potential to elicit such a molecular event, a 
more quantitative understanding of MIEs and KEs may also be achieved with predictive models 
[291]. For this, potency measurements, i.e. dose response relationships, of substances inducing MIEs 
and biological events further down the pathway are necessary in order to establish the relationship 
between these biological events [291]. Once more nephrotoxicity-related AOPs have been 
developed, an AOP-derived in silico framework would provide the robustness needed for a model to 
reliably inform screening of new drug candidates, and efforts to prioritise substances for further 
testing.  
With regard to developing better in silico modelling frameworks it is the development of SAs which 
is the logical starting point. These need to be refined and extended in order to facilitate the 
prediction of the hazard potential of a more comprehensive array of compounds. For instance, much 
existing knowledge on SAs has been compiled [292]. The existing knowledge needs to be rationalised 
such that a robust set of SAs can be established. Such an “in silico profiler” will assist in the 
designing-out of toxicity as well as grouping, allowing for read-across, especially to estimate the 
chronic toxicity of data-poor substances. A potentially rich source of information to develop further 
structural information are the data resultant from ToxCast. It has been shown that fingerprints using 
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available ToxCast data on kidney tissue cell lines may be developed [293]. Such fingerprints could 
consist of a defined number of in vitro assays reflecting the toxic mechanism of a specific group of 
known nephrotoxicants. If a new chemical is shown to generate hits according to one of the defined 
fingerprints, the likelihood of the chemical to cause nephrotoxic effects is considered to be high. 
Of the in silico models developed so far, there is always a place for QSARs, but only where suitable 
data allow. These may be based, for instance, around in vitro data for specific effects as opposed to 
the more ambitious modelling of whole organism toxicity. To facilitate better QSARs, besides 
incorporating data related to the toxicodynamics of a compound in the kidney, accounting for 
toxicokinetics and the potential of a substance to accumulate at a specific site within the kidney is 
considered to be equally important as an adverse effect may be caused due to supersaturation of 
parts of renal system. In vitro analyses indicate that many chemicals elicit toxicity via unspecific 
cytotoxicity [223,225,294]. Therefore, a mechanistic model simulating the toxicokinetics of 
compounds in the different parts of a nephron would help to understand whether a substance may 
be accumulating or not. Overall, it is clear that experimental and computational efforts have to go 
hand in hand, along with development of mechanistic knowledge, to achieve much-needed progress 
in this area. 
 
Methods: 
The scientific literature available via Google Scholar, ScienceDirect, PubMed, Web of Science and 
Scopus was reviewed for nephrotoxic substances, information related to mechanisms of 
nephrotoxicity and existing computational models to predict nephrotoxicity. Nephrotoxicants and 
mechanistic data were identified by searching the terms “drug-induced nephrotoxicity” OR “drug-
induced kidney toxicity” OR “drug-induced kidney injury” OR “drug-induced kidney damage” OR 
“drug-induced urinary tract toxicity”, and “chemical-induced nephrotoxicity” OR “chemical-induced 
kidney toxicity” OR “chemical-induced kidney injury” OR “chemical-induced kidney damage” OR 
“chemical-induced urinary tract toxicity”. Nephrotoxicants were also identified from the combined 
COSMOS and Munro dataset and the Toxicity Reference Database (ToxRefDB). The combined 
COSMOS and Munro dataset was exported from the COSMOS Database [118, 
https://cosmosdb.eu/cosmosdb.v2/accounts/login/?next=/cosmosdb.v2/ > Computational Methods 
> TTC Export], and only molecules for which “kidney” or “urinalysis parameters” are recorded first as 
critical effects were added to the list of nephrotoxicants. Besides information on critical effects 
stated in the combined COSMOS and Munro dataset, the species and, if available, kidney-related 
critical effect details were added. The ToxRefDB, which contains lowest effect levels (LELs) of over 
800 molecules for over 1’000 endpoints (e.g. 
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SUB_rat_SystemicCarcinogenic_adult_Urinary_UrinaryBladder, where SUB stands for subchronic), 
was downloaded from the U.S. EPA Toxicity ForeCaster (ToxCastTM) Data website [126, 
https://www.epa.gov/chemical-research/toxicity-forecaster-toxcasttm-data]. A compound was 
added to the nephrotoxicants’ list if its lowest LEL was only associated with kidney or urinary bladder 
related endpoints. SMILES codes of identified nephrotoxicants were sourced from Drugbank 
[195,196, https://www.drugbank.ca/], PubChem [199,200, 
https://pubchem.ncbi.nlm.nih.gov/search/], and ChemIDplus [189, 
https://chem.nlm.nih.gov/chemidplus/]. In silico models were queried by using the terms ‘’structural 
alerts’’ OR “structural fragments” OR “in silico” OR “QSAR” OR “mechanistic model” OR 
“mathematical model” AND ‘’nephrotoxicity’’ OR “kidney toxicity” OR “kidney injury” OR “kidney 
damage” OR ‘’urinary tract toxicity’’.  
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Appendix A: Kidney assay data available in the ToxCastTM Dashboard  
AssayComponentEndpointName BiologicalProcessTarget AssayFunctionType GeneName IntendedTargetFamily Organism 
NVS_ENZ_pMTHFR regulation of catalytic 
activity 
enzymatic activity methylenetetrahydrofolate 
reductase (NAD(P)H) 
oxidoreductase pig 
NVS_ENZ_pMTHFR_Activator regulation of catalytic 
activity 
enzymatic activity methylenetetrahydrofolate 
reductase (NAD(P)H) 
oxidoreductase pig 
NVS_MP_rPBR receptor binding binding translocator protein transporter rat 
OT_AR_ARSRC1_0480 protein stabilization binding androgen receptor nuclear receptor human 
OT_AR_ARSRC1_0960 protein stabilization binding androgen receptor nuclear receptor human 
OT_ER_ERaERa_0480 protein stabilization binding estrogen receptor 1 nuclear receptor human 
OT_ER_ERaERa_1440 protein stabilization binding estrogen receptor 1 nuclear receptor human 
OT_ER_ERaERb_0480 protein stabilization binding estrogen receptor 1 nuclear receptor human 
OT_ER_ERaERb_1440 protein stabilization binding estrogen receptor 1 nuclear receptor human 
OT_ER_ERbERb_0480 protein stabilization binding estrogen receptor 2 (ER 
beta) 
nuclear receptor human 
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OT_ER_ERbERb_1440 protein stabilization binding estrogen receptor 2 (ER 
beta) 
nuclear receptor human 
OT_FXR_FXRSRC1_0480 protein stabilization binding nuclear receptor subfamily 
1, group H, member 4 
nuclear receptor human 
OT_FXR_FXRSRC1_1440 protein stabilization binding nuclear receptor subfamily 
1, group H, member 4 
nuclear receptor human 
OT_NURR1_NURR1RXRa_0480 protein stabilization binding retinoid X receptor, alpha nuclear receptor human 
OT_NURR1_NURR1RXRa_1440 protein stabilization binding retinoid X receptor, alpha nuclear receptor human 
OT_PPARg_PPARgSRC1_0480 protein stabilization binding peroxisome proliferator-
activated receptor gamma 
nuclear receptor human 
OT_PPARg_PPARgSRC1_1440 protein stabilization binding peroxisome proliferator-
activated receptor gamma 
nuclear receptor human 
TOX21_AR_BLA_Agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_AR_BLA_Agonist_ch2 regulation of transcription 
factor activity 
reporter gene null background measurement human 
TOX21_AR_BLA_Agonist_ratio regulation of transcription 
factor activity 
reporter gene androgen receptor nuclear receptor human 
TOX21_AR_BLA_Antagonist_ratio regulation of transcription 
factor activity 
reporter gene androgen receptor nuclear receptor human 
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TOX21_AR_BLA_Antagonist_viability cell proliferation viability null cell cycle human 
TOX21_AutoFluor_HEK293_Cell_blue NA background control null background measurement human 
TOX21_AutoFluor_HEK293_Cell_green NA background control null background measurement human 
TOX21_AutoFluor_HEK293_Cell_red NA background control null background measurement human 
TOX21_AutoFluor_HEK293_Media_blue NA background control null background measurement human 
TOX21_AutoFluor_HEK293_Media_green NA background control null background measurement human 
TOX21_AutoFluor_HEK293_Media_red NA background control null background measurement human 
TOX21_ELG1_LUC_Agonist regulation of transcription 
factor activity 
reporter gene ATPase family, AAA 
domain containing 5 
hydrolase human 
TOX21_ERa_BLA_Agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_ERa_BLA_Agonist_ch2 regulation of transcription 
factor activity 
reporter gene null background measurement human 
TOX21_ERa_BLA_Agonist_ratio regulation of transcription 
factor activity 
reporter gene estrogen receptor 1 nuclear receptor human 
TOX21_ERa_BLA_Antagonist_ratio regulation of transcription 
factor activity 
reporter gene estrogen receptor 1 nuclear receptor human 
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TOX21_ERa_BLA_Antagonist_viability cell proliferation viability null cell cycle human 
TOX21_PPARg_BLA_Agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARg_BLA_Agonist_ch2 regulation of transcription 
factor activity 
reporter gene null background measurement human 
TOX21_PPARg_BLA_Agonist_ratio regulation of transcription 
factor activity 
reporter gene peroxisome proliferator-
activated receptor gamma 
nuclear receptor human 
TOX21_FXR_BLA_agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_FXR_BLA_agonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_FXR_BLA_agonist_ratio regulation of transcription 
factor activity 
reporter gene nuclear receptor subfamily 
1, group H, member 4 
nuclear receptor human 
TOX21_FXR_BLA_antagonist_ratio regulation of transcription 
factor activity 
reporter gene nuclear receptor subfamily 
1, group H, member 4 
nuclear receptor human 
TOX21_FXR_BLA_antagonist_viability cell proliferation viability null cell cycle human 
TOX21_PPARd_BLA_agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
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TOX21_PPARd_BLA_agonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARd_BLA_agonist_ratio regulation of transcription 
factor activity 
reporter gene peroxisome proliferator-
activated receptor delta 
nuclear receptor human 
TOX21_PPARd_BLA_antagonist_ratio regulation of transcription 
factor activity 
reporter gene peroxisome proliferator-
activated receptor delta 
nuclear receptor human 
TOX21_PPARd_BLA_antagonist_viability cell proliferation viability null cell cycle human 
TOX21_PPARg_BLA_antagonist_ratio regulation of transcription 
factor activity 
reporter gene peroxisome proliferator-
activated receptor gamma 
nuclear receptor human 
TOX21_PPARg_BLA_antagonist_viability cell proliferation viability null cell cycle human 
TOX21_VDR_BLA_agonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_VDR_BLA_agonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_VDR_BLA_agonist_ratio regulation of transcription 
factor activity 
reporter gene cytochrome P450, family 
24, subfamily A, 
polypeptide 1 
cyp human 
TOX21_VDR_BLA_antagonist_ratio regulation of transcription 
factor activity 
reporter gene cytochrome P450, family 
24, subfamily A, 
polypeptide 1 
cyp human 
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TOX21_VDR_BLA_antagonist_viability cell proliferation viability null cell cycle human 
TOX21_FXR_BLA_agonist_viability cell proliferation viability null cell cycle human 
TOX21_ERa_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_ERa_BLA_Antagonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_FXR_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_FXR_BLA_Antagonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARd_BLA_Agonist_viability cell proliferation viability null cell cycle human 
TOX21_PPARd_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARd_BLA_Antagonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARg_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_PPARg_BLA_Antagonist_ch2 regulation of transcription background control null background measurement human 
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factor activity 
TOX21_VDR_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_VDR_BLA_Antagonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_AR_BLA_Antagonist_ch1 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_AR_BLA_Antagonist_ch2 regulation of transcription 
factor activity 
background control null background measurement human 
TOX21_VDR_BLA_Agonist_viability cell proliferation viability null cell cycle human 
NCCT_HEK293T_CellTiterGLO cytotoxicity viability null cell cycle human 
For additional information on assays, please reference the ToxCastTM dashboard. 
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Appendix B: Kidney and urinary bladder related toxicity endpoints available in ToxRefDB 
SUB_dog_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
CHR_dog_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
CHR_mouse_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
CHR_mouse_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_Kidney 
CHR_mouse_SystemicCarcinogenic_adult_PathologyNeoplastic_Urinary_Kidney 
CHR_mouse_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
CHR_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
CHR_rat_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_Kidney 
CHR_rat_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
CHR_rat_SystemicCarcinogenic_adult_PathologyNeoplastic_Urinary_Kidney 
SUB_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
SUB_rat_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
SUB_rat_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_Kidney 
DEV_rat_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
DEV_rabbit_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
MGR_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
MGR_rat_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_Kidney 
MGR_rat_SystemicCarcinogenic_adult_PathologyGross_Urinary_Kidney 
SUB_mouse_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_Kidney 
SUB_mouse_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_Kidney 
SUB_dog_SystemicCarcinogenic_adult_Urinary_Kidney 
CHR_dog_SystemicCarcinogenic_adult_Urinary_Kidney 
CHR_mouse_SystemicCarcinogenic_adult_Urinary_Kidney 
CHR_rat_SystemicCarcinogenic_adult_Urinary_Kidney 
SUB_rat_SystemicCarcinogenic_adult_Urinary_Kidney 
DEV_rat_SystemicCarcinogenic_adult_Urinary_Kidney 
DEV_rabbit_SystemicCarcinogenic_adult_Urinary_Kidney 
MGR_rat_SystemicCarcinogenic_adult_Urinary_Kidney 
MGR_rat_SystemicCarcinogenic_juvenile_Urinary_Kidney 
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SUB_mouse_SystemicCarcinogenic_adult_Urinary_Kidney 
 
CHR_mouse_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_UrinaryBladder 
CHR_mouse_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_UrinaryBladder 
CHR_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_UrinaryBladder 
CHR_rat_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_UrinaryBladder 
CHR_rat_SystemicCarcinogenic_adult_PathologyNeoplastic_Urinary_UrinaryBladder 
SUB_rat_SystemicCarcinogenic_adult_PathologyProliferative_Urinary_UrinaryBladder 
SUB_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_Urinary_UrinaryBladder 
SUB_rat_SystemicCarcinogenic_adult_PathologyGross_Urinary_UrinaryBladder 
CHR_dog_SystemicCarcinogenic_adult_Urinary_UrinaryBladder 
CHR_mouse_SystemicCarcinogenic_adult_Urinary_UrinaryBladder 
CHR_rat_SystemicCarcinogenic_adult_Urinary_UrinaryBladder 
SUB_rat_SystemicCarcinogenic_adult_Urinary_UrinaryBladder 
SUB_mouse_SystemicCarcinogenic_adult_Urinary_UrinaryBladder 
CHR=chronic/cancer; MGR=multigenerational reproductive; DEV=prenatal developmental; 
SUB=subchronic; 
 
Appendix C: Description of (Q)SAR models associated with kidney and bladder toxicity 
C.1 Munday et al. [262] 
Munday et al. [262] aimed to derive structural alerts for rat nephrotoxicity from 16 1,2- and 1,4-
naphthoquinones. Some naphthoquinones, e.g. 2-hydroxy-1,4-naphthoquinone  and 2-amino-1,4-
naphthoquinone, had been found to be nephrotoxic, mainly causing renal tubular necrosis in rats 
associated with presence of casts in the tubules [262,271,272]. 2-hydroxy-1,4-naphthoquinone, the 
active component in henna, produced fatal renal tubular necrosis in a child who was cutaneously 
treated with henna [273]. The mechanism of renal tubular necrosis induced by the 1,4-
naphthoquinones was, and still appears to be, unknown. Munday et al. [262,272] hypothesised that 
nephrotoxicity was a result of tautomerism of hydroxyl or amino 1,4-quinolones to strongly reactive 
1,2-naphthoquinones or 1,2-naphthoquinoneimines. However, the results of the study suggest that 
this hypothesis is wrong. The results did not allow for the definitive identification of structural 
features associated with naphthoquinone-induced nephrotoxicity or the conclusive determination of 
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the mechanism. However, this study confirmed that 2-hydroxy-1,4-naphthoquinone and 4-amino-
1,2,-naphthoquinone were extremely toxic to the kidney. Several alterations in structure of the 
above compounds caused the following changes in their toxic effect to the kidney: methylation of 
the amino group substantially increased nephrotoxicity, whilst methylation of the hydroxyl group, 
arylation of the amino-group and substitution with a chloro or amino group in the 3-position of the 
quinone ring eliminated nephrotoxicity. It was also found that substitution with small substituents 
i.e. methyl or ethyl decreases the extent of renal tubular damage – the larger the size of alkyl group, 
the greater the reduction of renal damage.  
 
C.2 Pizzo et al. [263] 
Pizzo et al. [263] conducted a study to evaluate, identify and group substructures into six structural 
alerts recognised as being toxic to the kidney and / or urinary tract using repeated-dose toxicity 
studies on rats taken from the Hazard Evaluation Support System (HESS) database. SAs were 
selected based on their likelihood ratio (LR) and percentage of true positives. These alerts were 
encoded as SMARTS (SMiles ARbitrary Target Specification). A plausible mechanistic explanation for 
these substructures to cause nephrotoxicity was only provided for the 2nd, 3rd, 5th and 6th SAs.  
 
The 2nd SA identified is sulphanilamide, which belongs to the class of sulphonamides. According to 
the literature, sulphonamides can cause obstructive nephropathy as they are insoluble in acidic 
urine, which causes them to precipitate as crystals in the tubules [87]. SA 3 is found in benzonitriles 
which have been reported to be harmful to the kidney due to adverse effects leading to cytotoxicity 
in the human embryonic renal cell line HEK293T [274]. SA 5 is chloroform, which is also reported as a 
structural alert in other studies, including Myshkin et al. [265]. Chloroform is believed to cause 
nephrotoxicity via metabolism by P450 enzymes into toxic metabolites which may induce renal 
cancer through cytotoxicity eliciting regenerative cell proliferation [274]. SA 6 is biphenyl; according 
to Pizzo et al. [263], biphenyl was identified seven times in the dataset of 89 active kidney toxicants, 
out of which five cases were found in nephrotoxic molecules. Biphenyls cause haematuria, increased 
urinary pH, formation of calculi inducing urinary tract tumours [263,275]. According to ChemDraw 
Professional (version:16.0.1.4 (77)), SA 1 and 4 are benzenesulfonic acid and hepta-1,5-diene, 
respectively. Most of the above alerts were reproduced in the study by Myshkin et al. [265]. 
 
C.3 Derek Nexus  
Derek Nexus is a knowledge-based expert system that uses SAs to provide in silico prediction of 
toxicity [264]. As well as the key mechanisms mentioned earlier, Derek Nexus may identify 
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compounds elicting nephrotoxicity via additional mechanisms. Examples of these mechanisms 
include: necrosis and fibrosis of the renal medullary interstitium; drug-induced ureteral obstruction 
(when drug causes blockage in one or both of the ureters leading from kidneys to the bladder) and 
drug-induced formation of cholesterol emboli. Also, Derek Nexus EREK may trigger a warning for 
α2μ-globulin nephropathy. Any structural alerts are identified in the original structure as highlighted 
toxicophores. A list of key literature references is provided, along with, in some cases, a proposed 
mechanism.  
 
C.4 Myshkin et al. [265] 
Myshkin et al. [265] described the construction and validation of QSAR models based on a database 
of organ-level toxicity and the identification of toxicophores. QSAR models were generated to 
predict organ toxicity endpoints, including “nephrotoxicity” with subcategories for “kidney necrosis”, 
“kidney relative weight gain” and “nephron injury”, using a recursive partitioning algorithm. 
According to the authors, the models demonstrated good predictive performance overall. When 
developing the compound sets, chemicals that were known to cause the toxicity (positives) and 
chemicals known not to cause toxicity (negatives) were included. The positives that were correctly 
predicted by the models were then clustered based on common toxicophore substructures by the 
JKlustor  5.9.0 utility from ChemAxon.  
 
A total of 192 toxicophores were identified for all nephrotoxicity endpoints. However, the 
endpoints ”kidney weight gain”, “nephron injury” and ”nephrotoxicity” are unspecific toxicity 
endpoints with regard to attempting to identify a mechanistic explanation for the nephrotoxic effect. 
These three endpoints could be associated with all of the nephrotoxicity pathways discussed in more 
detail below. Some of the substructures identified by Myskin et al. [265] were also identified in the 
other studies mentioned above; for example, chloroform, providing further justification and 
confirmation. In addition, some of the substructures identified are also relatively unspecific, e.g. 
cyclohexane or chlorobenzene. In the case of chlorobenzene, some more specific related 
substructures have been proposed, such as 1,2-dichlorobenzene, 1,3-dichlorobenzene or 4-
chlorophenol. For this reason, it may be useful to study these substructures in more detail and find 
more defined alerts relating to nephrotoxicity. 
 
C.5 Jolivette and Anders [266]  
Jolivette and Anders [266] developed a linear QSAR model to predict the nephrotoxicity of 9 
haloalkenes. Haloalkenes are high-volume chemicals and common environmental pollutants. 
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Bioactivation of haloalkanes occurs to form reactive intermediates. This process involves the 
formation of hepatic glutathione S-conjugates, which are then hydrolysed by peptidases into 
cysteine S-conjugates. Cysteine S-conjugates subsequently undergo bioactivation, by renal cysteine 
conjugate lyases, to form the nephrotoxic intermediates. The reaction of glutathione with 
haloalkenes is catalysed by microsomal (MGST1) and cytosolic glutathione transferases (cGST) [266]. 
In this study, a computational chemistry approach was used to test the hypothesis that an SAR exists 
and that ELUMO (energies of the lowest unoccupied molecular orbitals) values can be used to predict 
the ability of rat liver MGST1 to catalyse the reaction of glutathione with haloalkenes. No, or a low 
level of, conjugate formation was detected for four of the nine molecules investigated. A linear 
relationship was found between the natural logarithms of the specific activities for the glutathione 
conjugation reaction catalysed by rat liver MGST1 and ELUMO values for hexafluoropropene, 2-
(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene, 1,1,2-trichloro-3,3,3-trifluoro-1-propene and 1,1-
dibromo-2,2-difluoroethene. This linear relationship corresponds only to four data points and cannot 
be extrapolated to ELUMO values outside of the range -1.14 to -0.73 eV. When the ELUMO value for 
tetrachloroethene was added to those of the previously mentioned four compounds and compared 
with the natural logarithms, a linear relationship was not seen. It was found that haloalkenes with 
more negative ELUMO values demonstrate a greater specific activity for the enzyme-catalysed reaction 
of glutathione conjugation than haloalkenes with less negative ELUMO values. This indicates that the 
chemical reactivity of the substrate plays a crucial role in the rate at which the glutathione-
dependent biotransformation of the haloalkenes takes place.  
 
C.6 Barratt [99] 
α2μ-globulin nephropathy occurs in male rats as a result of a compound’s binding affinity to α2μ-
globulin, which causes the chemical-protein complex to accumulate in renal lysosomes [99]. This 
leads to tubular necrosis and eventually cell death. Barratt [99] derived two QSAR models to screen 
for the potential of a compound to induce α2μ-globulin nephropathy by multiple regression analysis 
and principal components analysis using the following properties: negative charge density of the 
binding molecule, molecular volume, and inertial axis lengths. The QSAR model based on multiple 
regression analysis alone did not accommodate all of the molecular features that allowed accurate 
predictions of chemicals that may cause α2μ-globulin nephropathy. Therefore, a previous dataset by 
Bomhard et al. [276] consisting of 43 aliphatic and alicyclic hydrocarbon structures was added and 
subjected to a principal components analysis. The toxicological endpoint assessed in Bomhard et al. 
[276] was α2μ-accumulation in renal lysosomes in male rats. It was found that for a molecule to 
cause α2μ-globulin nephropathy, its size and shape should be so that it fits with the binding site on 
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α2μ-globulin. It should also have a hydrogen bond acceptor. Lastly, hydrophobic interactions were 
found to be a contributing factor but not to a significant extent when included in either QSAR. The 
shape, size and electronegativity elements related to active compounds were incorporated in both 
QSARs.  
 
Barratt [99] concluded that the combination of the two QSARs is useful in identifying molecular 
structures with a potential to cause α2μ-globulin nephropathy. The applicability domain of both 
QSARs was not discussed. Furthermore, α2μ-globulin nephropathy has been acknowledged as an 
adverse effect specific to male rats and little relevant to human health as α2μ-globulin is not 
synthesised in the human liver [99]. Hence, these models may only be applied to assess whether 
compounds which have been linked to nephrotoxicity in male rats induce these effects via the α2μ-
globulin pathway.  
 
C.7 Lee et al. [252] 
Lee et al. [252] developed binary classification QSAR prediction models for three nephrotoxicity 
mechanisms: tubular necrosis, interstitial nephritis, and tubulo-interstitial nephritis. These models 
were built using two data sets, i.e. parent compounds (251 nephrotoxicants and 387 non-
nephrotoxicants) and their urinary metabolites (307 nephrotoxicants and 233 non-nephrotoxicants) 
based on clinical trials and post-marketing surveillance reports. A list of the parent and metabolite 
compounds was not published. Models were computed using a support vector machine and 20 
descriptors with highest information gains in the form of eight different fingerprints for parent and 
metabolite sets and each of the three mechanisms. According to the authors, the predicted 
accuracies of the models for each type of kidney injury were better than 83% for external validation 
sets. This indicates that the models used could prove to be useful in identifying potentially 
nephrotoxic compounds.  
 
Substructural fragments were analysed and were documented alongside the frequency of fragment 
enrichment factors. The selected eight substructures were common to both datasets for all of the 
above three nephrotoxicity mechanisms. Lee et al. [252] concluded that consideration of the 
metabolism of a chemical is important to predict its nephrotoxicity potential. When comparing the 
number of nephrotoxicants and non-nephrotoxicants with a specified fragment of the metabolite set 
to respective numbers of the parent compound set, the number of nephrotoxicant metabolites 
increased dramatically. This is due to the bioactivation of a potentially non-nephrotoxic compound 
into a toxic metabolite. Also, when these alerts were compared approximately to those found by 
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Pizzo et al. [263], similarities were not observed at first sight. Lee et al. [252] have provided a link 
that offers free access to the software on their website. However, this link does not appear to be 
working at this time: http://bmdrc.org/DemoDownload. 
 
C.8 Matthews et al. [267] 
Matthews et al. [267] created QSAR models to predict drug-induced urinary tract toxicity in humans 
on the basis of adverse events reported post marketing approval. Six endpoints of urinary tract 
injury were considered, namely nephropathies, acute renal disorders, bladder disorders, blood in 
urine, urolithiases and kidney function tests. Four QSAR approaches were applied using the following 
software: MC4PC, BioEpisteme, MDL QSAR and Leadscope Predictive Data Miner. The best 
predictive performance was achieved for the endpoints kidney function test with 87.7% specificity, 
43.3% sensitivity and 91.6% coverage, and nephropathies with of 81.5% specificity, 49.5% sensitivity 
and 91.4% coverage. One of the limitations of these models is the variable quality of the post-
marketing reported adverse event data used which may be compromised through non-uniform 
reporting of an adverse effect and its occurrence in patients who are often subject to multi-drug 
therapy. 
 
C.9 Antczak et al. [268] 
This study aimed to link physico-chemical features to drug-induced transcriptional responses and 
phenotypic outcome using a multivariate statistical approach. A number of KEGG pathways, which 
were reported to be significantly perturbed by nephrotoxic compounds under consideration in this 
study, may be specifically associated with nephrotoxicity [268]. The model showed that nephrotoxic 
substances are characterised by high polarisability, low electronegativity and low molecular 
symmetry. 
 
C.10 Hammann et al. [269] 
For this study, Hammann et al. [269] use decision tree inference analysis, a machine learning 
method, based on the chemical, physical, and structural properties and adverse drug reactions of 
507 drugs. As decision tree inference algorithms, classification and regression tree (CART) and chi-
squared automatic interaction detector (CHAID) were selected. Both models performed well, with 
CART and CHAID model corrected classification rates (CCRs) of 88.6 and 84.7%, respectively. The 
CART model highlights that amine functions, sulphur, and carboaromatic ring structures have an 
influence on a drug’s potential to cause nephrotoxicity. For substances safer to the kidney, CHAID 
54 
 
model found few aromatic atoms (<19), a basic pKa <10.71, van der Waals surface area <1,014.5 Å2, 
and logP values >2.43. 
 
C.11 Lei et al. [270] 
Lei et al. [270] used a mouse intraperitoneal urinary tract toxicity data set of 258 chemicals from the 
ChemIDplus public database to develop eight qualitative and quantitative structure-activity 
relationship (QSAR), i.e. classification and regression, models to predict urinary tract toxicity. The 
recursive feature elimination method incorporated with random forests (RFE-RF) was applied for 
dimension reduction, followed by the utilisation of eight machine learning approaches for QSAR 
modelling, i.e., relevance vector machine (RVM), support vector machine (SVM), regularized random 
forest (RRF), C5.0 trees, eXtreme gradient boosting (XGBoost), AdaBoost.M1, SVM boosting 
(SVMBoost), and RVM boosting (RVMBoost). Among these, RVMBoost based on the RBF kernel 
accomplishes the best quantitative and qualitative predictions for the test set (MCC of 0.787, AUC of 
0.893, sensitivity of 89.6%, specificity of 94.1%, and global accuracy of 90.8%). All chemicals included 
in this study are within the application domain coverage. Overall, a reliable prediction is achieved by 
both regression and classification models developed by the SVMBoost approach. 
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